WO1998011098A1 - Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase - Google Patents

Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase Download PDF

Info

Publication number
WO1998011098A1
WO1998011098A1 PCT/US1997/015903 US9715903W WO9811098A1 WO 1998011098 A1 WO1998011098 A1 WO 1998011098A1 US 9715903 W US9715903 W US 9715903W WO 9811098 A1 WO9811098 A1 WO 9811098A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
benzo
cyclohepta
dihydro
Prior art date
Application number
PCT/US1997/015903
Other languages
French (fr)
Inventor
Alan B. Cooler
Alan K. Mallans
Viyyoor M. Girijavallabhan
Ronald J. Doll
Arthur G. Taveras
F. George Njoroge
John J. Baldwin
John C. Reader
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ334452A priority Critical patent/NZ334452A/en
Priority to EP97941477A priority patent/EP0931078B1/en
Priority to JP10513762A priority patent/JP2001500507A/en
Priority to IL12890797A priority patent/IL128907A0/en
Priority to HU0000191A priority patent/HUP0000191A2/en
Priority to AU43376/97A priority patent/AU4337697A/en
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to BR9712826-0A priority patent/BR9712826A/en
Priority to CA002265763A priority patent/CA2265763A1/en
Priority to SK330-99A priority patent/SK33099A3/en
Priority to DE69736950T priority patent/DE69736950T2/en
Publication of WO1998011098A1 publication Critical patent/WO1998011098A1/en
Priority to NO991233A priority patent/NO991233L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Definitions

  • Patent application WO 95/00497 published 5 January 1995 under the Patent Cooperation Treaty describes compounds which inhibit the enzyme, famesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras.
  • Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis.
  • Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non- transformed cells. Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer.
  • Ras oncoprotein To acquire transforming potential, the precursor of the Ras oncoprotein must undergo farnesylation of the cysteine residue located in a carboxyl- terminal tetrapeptide. Inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase, have therefore been suggested as anticancer agents for tumors in which Ras contributes to transformation. Mutated, oncogenic forms of Ras are frequently found in many human cancers, most notably in more than 50% of colon and pancreatic carcinomas (Kohl et al., Science, Vol. 260, 1834 to 1837, 1993). In view of the current interest in inhibitors of farnesyl protein transferase, a welcome contribution to the art would be additional compounds useful for the inhibition of farnesyl protein transferase. Such a contribution is provided by this invention.
  • this invention provides a method for inhibiting farnesyl protein transferase using tricyclic compounds of this invention which: (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro: (ii) block the phenotypic change induced by a form of transforming Ras which is a farnesyl acceptor but not by a form of transforming Ras engineered to be a geranylgeranyl acceptor; (iii) block intracellular processing of Ras which is a farnesyl acceptor but not of Ras engineered to be a geranylgeranyl acceptor; and (iv) block abnormal cell growth in culture induced by transforming Ras.
  • tricyclic compounds of this invention which: (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro: (ii) block the phenotypic change induced by a form of transforming Ras which is
  • This invention provides a method for inhibiting the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of this invention.
  • Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.
  • one of a, b, c and d represents N or NR 9 wherein R 9 is O", -CH3 or -(CH2)nC02H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR 1 or CR 2 ; or each of a, b, c, and d are independently selected from CR 1 or CR 2 ; each R 1 and each R 2 is independently selected from H, halo, -CF3, -OR 10 , -COR 10 , -SR 10 , -S(0) t R 11 (wherein t is 0, 1 or 2), -SCN, -N(R 10 ) 2 , -NR 0 R 1 1 , -N0 2 , -OC(0)R 1 °, -C0 2 R 10 , -OC0 2 R 11 , -CN, -NHC(0)R 10 , -NHS0 2
  • R 3 and R 4 are the same or different and each independently represents H, any of the substituents of R 1 and R 2 , or R 3 and R 4 taken together represent a saturated or unsaturated C5-C 7 fused ring to the benzene ring (Ring III);
  • R 10 represents H, alkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, aryl, aralkyl or -NR 40 R 42 wherein R 40 and R 42 independently represent H, aryl, alkyl, aralkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl;
  • T is -CO-; -SO-; -S0 -; or -CR 30 R 31 - wherein R 30 and R 31 independently represent H, alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; and Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR 40 , -SR 40 , -CR 40 R 42 , -NR 40 R 42 ,
  • n, R 40 and R 42 are defined hereinbefore, m is 2, 34, 5, 6, 7 or 8; q is 0 (zero), 1 or 2; and R 14 represents H, C ⁇ . 6 alkyl, aralkyl, heteroaryl, acyl, carboxamido, carboxamidoalkyl, cyano, alkoxycarbonyl, aralkyloxycarbonyl, D- and L-amino acids coval ⁇ ntly bonded through the carboxyl group, imido, imidamido, sulfamoyl, sulfonyl, dialkylphosphinyl, N-glycosyl,
  • a is N; b, c and d are carbon; A and B each represent H 2 and the optional double bond is absent.
  • R 1 and R 4 are H and R 2 and R 3 are halo selected from chloro and bromo; or R 1 is H and R 2 , R 3 and R 4 are halo selected from chloro and bromo.
  • R 2 and R 3 are halo in the 3- and the 8-position on the ring structure; or R 2 , R 3 and R 4 are in the 3-, 8- and 10- position on the ring structure.
  • R 2 is Br and R 3 is Cl in the 3- and the 8-position on the ring structure; or R 2 is Br, R 3 is Cl and R 4 is Br in the 3-, 8- and 10- position on the ring structure.
  • each of R 5 , R 6 , R 7 and R 8 is H.
  • the moiety -(CH2)n-T-Z is bonded at the 2-, 3- or 4-position on the piperdinyl ring, more preferably at the 2- or 3- position on the piperdinyl ring.
  • n is zero;
  • Z is -NR 40 R 42 wherein R 40 represents H and R 42 represents heteroarylalkyl. More preferably R 40 is H and R 42 is the heteroaryl moiety 3-pyridylmethyl.
  • the present invention is directed toward a pharmaceutical composition for inhibiting the abnormal growth of cells comprising an effective amount of compound (1.0) in combination with a pharmaceutically acceptable carrier.
  • the present invention is directed toward a method for inhibiting the abnormal growth of cells, including transformed cells, comprising administering an effective amount of compound (1.0) to a mammal (e.g., a human) in need of such treatment.
  • Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs, and (4) benign or malignant cells that are activated by mechanisms other than the Ras protein.
  • these compounds may function either through the inhibition of G-protein function, such as ras p21 , by blocking G-protein isoprenyiation, thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer, or through inhibition of ras farnesyl protein transferase, thus making them useful for their antiproliferative activity against ras transformed cells.
  • the cells to be inhibited can be tumor cells expressing an activated ras oncogene.
  • the types of cells that may be inhibited include pancreatic tumor cells, lung cancer cells, myeloid leukemia tumor cells, thyroid follicular tumor cells, myelodysplastic tumor cells, epidermal carcinoma tumor cells, bladder carcinoma tumor cells or colon tumors cells.
  • the inhibition of the abnormal growth of cells by the treatment with compound (1.0) may be by inhibiting ras farnesyl protein transferase.
  • the inhibition may be of tumor cells wherein the Ras protein is activated as a result of oncogenic mutation in genes other than the Ras gene.
  • compounds (1.0) may inhibit tumor cells activated by a protein other than the Ras protein.
  • This invention also provides a method for inhibiting tumor growth by administering an effective amount of compound (1.0) to a mammal (e.g., a human) in need of such treatment.
  • a mammal e.g., a human
  • this invention provides a method for inhibiting the growth of tumors expressing an activated Ras oncogene by the administration of an effective amount of the above described compounds.
  • tumors which may be inhibited include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma and epidermal carcinoma.
  • lung cancer e.g., lung adenocarcinoma
  • pancreatic cancers e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma
  • colon cancers e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma
  • myeloid leukemias for
  • this invention also provides a method for inhibiting proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes-i.e., the Ras gene itself is not activated by mutation to an oncogenic form-with said inhibition being accomplished by the administration of an effective amount of the carbonyl piperazinyl and piperidinyl compounds (1.0) described herein, to a mammal (e.g., a human) in need of such treatment.
  • a mammal e.g., a human
  • the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited by the carbonyl piperazinyl and piperidinyl compounds (1.0) described herein.
  • the present invention is directed toward a method for inhibiting ras farnesyl protein transferase and the farnesylation of the oncogene protein Ras by administering an effective amount of compound (1.0) to mammals, especially humans.
  • the administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase is useful in the treatment of the cancers described above.
  • MH+ represents the molecular ion plus hydrogen of the molecule in the mass spectrum
  • acyl-a moiety of the formula -COR 15 wherein R 15 represents H, C-i -6alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl or -(CH2)_NR 80 R 81 wherein k is 1 or 2, and R 80 and R 81 may independently represent H, alkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl or aralkyl; alkyl-(including the alkyl portions of alkoxy, alkylamino and dialkylamino)-represents straight and branched carbon chains and contains from one to twenty carbon atoms, preferably one to six carbon atoms (i.e.
  • Representative amino acids include glycine, serine, alanine, phenylalanine, tyrosine, S-methyl methionine and histidine; aryl (including the aryl portion of aralkyl)-represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is phenyl), wherein said aryl group optionally can be fused with aryl, cycloalkyl, heteroaryl or heterocycloalkyl rings; and wherein any of the available substitutable carbon and nitrogen atoms in said aryl group and/or said fused ring(s) may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -
  • heteroaryl groups can include, for example, furanyl, imidazoyl, pyrimidinyl, triazolyl, 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl N-oxide wherein pyridyl N-oxide can be represented as:
  • heteroarylalkyl - represents an alkyl group, as defined above, wherein one or more hydrogen atoms have been replaced by one or more heteroaryl groups; wherein said heteroarylalkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -S0 2 NH 2 , -NHSO2R 10 , -S0 2 NHR 1 °, -S0 2 R 10 , -SOR 10 , -SR 10 , -NHSO2, -N0 2 , -CONR 10 , -NCOR 10 or -COOR 10 ; as exemplified by 2-, 3- or 4-pyr idylmethyl or 2-, 3- or 4-pyridylmethyl N-oxide; heterocycloal
  • heterocycloalkyl groups can include morpholinyl, 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 1-, 2-, 3- or 4-piperidinyl, 2- or 3- — N S(O), pyrrolidinyl, 1-, 2- or 3-piperizinyl, 2- or 4-dioxanyl, or wherein t is 0, 1 or 2;
  • heterocycloalkylalkyl- represents an alkyl group, as defined above, wherein one or more hydrogen atoms have been replaced by one or more heterocycloalkyl groups; wherein optionally, said ring may contain one or two unsaturated bonds which do not impart aromatic character to the ring; and wherein said heterocycloalkylalkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy,
  • R 50 represents H, cyano, aryl, -S ⁇ 2 H 2 ,
  • -SO 2 NR 40 R 42 and carboxamido and R 51 represents aryl and aryloxy.
  • Representative imido groups can include, for example,
  • imidamido - represents a moiety of the formula
  • R 55 represents H, cyano, -S ⁇ 2NH 2 , -SO 2 NR 40 R 42 , carboxamido, hydroxy and alkoxy.
  • Representative imidamido groups can include, for example,
  • N-glycosyl- represents a pyranosyl or furanosyl monosaccaride.
  • Representative N-glycosyl groups include (N — * ⁇ 1)-tetra-0-acetyl-D-glucosyl, (N -* ⁇ 1)-tetra-0-acetyl-D-galactosyl and (N -*" 1) -tri-O-acetyl-D-ribosyl, e.g.
  • a representative dialkylphosphinyl group is
  • sulfamoyl - represents a moiety of the formula -SO2R 60 wherein R 60 represents amino, alkylamino and dialkylamino.
  • Representative sulfamoyl groups can include, for example, -S0 2 NH 2 , -SO2NHCH3, -S0 N(CH 3 )2.
  • sulfonyl - represents a moiety of the formula -SO2R 60 wherein R 60 represents alkyl, aryl and arylalkyl.
  • Representative sulfonyl groups can include, for example, -S0 CH 3 , -S ⁇ 2C 6 H 5 , -S0 2 C6H 4 CH 3 , and
  • Certain compounds of the invention may exist in different stereoisomeric forms (e.g., isomers such as enantiomers and diastereoisomers).
  • the invention contemplates all such stereoisomers both in pure form and in mixture, including racemic mixtures.
  • the carbon atom at the C-11 position can be in the S or R stereoconfiguration.
  • the carbon atom at the C-2, C-3, C-5 and C-6 positions of the piperidinyl moiety bonded at C-11 can also be in the S or R stereoconfiguration.
  • Certain tricyclic compounds will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts.
  • salts may include sodium, potassium, calcium, aluminum, gold and silver salts.
  • salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N- methylglucamine and the like.
  • Certain basic tricyclic compounds also form pharmaceutically acceptable salts, e.g., acid addition salts.
  • the pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids.
  • suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art.
  • the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
  • the free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
  • a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate.
  • the free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention. All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
  • L represents a leaving group such as halo, preferably chloro or a leaving group such as o-tosyl and o-mesyl; the dotted line represents a single or double bond; and a, b, c, d, A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , n, T and Z are as defined hereinbefore.
  • compounds of formula (5.0) can be prepared by reacting the compounds of formula (3.0) with a halogenating agent or a sulfonylating agent in the presence of a suitable base, and optional aprotic solvent, in amounts and under conditions effective to give compounds (5.0).
  • Suitable bases include organic bases such as pyridine and triethylamine; or inorganic bases of alkali and alkaline earth metals including carbonates such as sodium, lithium, potassium and cesium carbonates, hydroxides such as sodium, lithium and potassium hydroxides; hydrides such as sodium or potassium hydride; and sodium t-butoxide, preferably sodium hydride.
  • Suitable aprotic solvents include ethers, DMF, DMSO, THF, DME and mixtures thereof, preferably DMF.
  • the halogenating agent is a chlorinating agent, such as thionyl chloride.
  • the sulfonylating can be methane sulfonyl chloride or toluene sulfonyl chloride.
  • the amounts of the halogenating agent or the sulfonylating agent can range from about one to about 10 moles per mole of compound (3.0). Temperatures can range from 0° to 50°C, or reflux of the reaction mixture.
  • the desired tricylic piperidinyl compounds of formula (1.0) can be prepared by reacting the compounds of formula (5.0) with a suitably substituted piperidinyl compound of formula (7.0) in the presence of a suitable base and optional aprotic solvent, such as those described above, to give compounds (1.0).
  • the amounts of the substituted piperidinyl compound of formula (7.0) to compound (5.0) can range from about one to about 10 moles per mole of compound (5.0)
  • Temperatures can range from about room temperature to about 80°C.
  • the tricylic piperidinyl compounds of fomula (1.0) can be isolated from the reaction mixture using conventional procedures, such as, for example, extraction of the reaction mixture from water with organic solvents, evaporation of the organic solvents, followed by chromatography on silica gel or other suitable chromatographic media.
  • L represents a leaving group, preferably chloro; the dotted line represents a single or double bond; and a, b, c, d, A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 8 , R 11 , R 40 , R 42 and n are as defined hereinbefore.
  • compounds of formula (8.0) can be prepared by reacting the compounds of formula (5.0) with a piperdinyl carboxylic acid ester of formula (7.5 ) in the presence of a base and optional aprotic solvent, in amounts and under conditions effective to give compounds (8.0). Suitable bases and aprotic solvents are described hereinbefore.
  • the amounts of piperidinyl compound (7.5) can range from about 1 to about 10 moles per mole of compound (5.0). Temperatures can range from room temperature to about 80°C.
  • Compound (8.0) can be isolated as described hereinbefore.
  • Carboxylic acid compounds of formula (8.5) can be prepared by hydrolyzing carboxylic acid ester (8.0) with an excess amount of acid or base.
  • Suitable acids include inorganic acids, organic acids or a mixture thereof.
  • Inorganic acids include hydrogen chloride, hydrogen bromide, sulfuric acid, nitric acid, phosphoric acid, perchloric acid and the like.
  • Organic acids include acetic, citric, formic, maleic, tartaric, methanesulfonic acid and arylsulfonic acids.
  • Suitable bases such as sodium hydroxide or lithium hydroxide, preferably in an aqueous alcohol, have been described hereinbefore.
  • the temperature can range from about 0°C to about 100°C.
  • the desired amide compounds of formula (1.1) can be prepared by reacting the compounds of formula (8.5) with a suitable amine of formula (9.0) in the presence of a coupling agent such as DEC/HOBT, a base such as NMM and a suitable aprotic solvent effective to give amide compound (1.1 ).
  • a coupling agent such as DEC/HOBT
  • a base such as NMM
  • a suitable aprotic solvent effective to give amide compound (1.1 ).
  • Suitable bases and aprotic solvents are described hereinbefore.
  • the amounts of amine (9.0) can range from about 1 to about 10 moles per mole of carboxylic acid (8.5). Temperatures can range from 0° to 100°C.
  • Compound (1.1 ) can be isolated as described hereinbefore.
  • N-substituent CH 122.3, 149.9, 149.9, 122.3
  • N-substituent CH 123.6, 136.9, 121.7, 149.0
  • Chloroethoxycarbonyl chloride (0.09027ml; 1 equivalent) is added over 5 minutes and the solution is allowed to warm to 25°C over 1 h.
  • the dichloromethane is removed in vacuo and anhydrous methanol (14ml) is added.
  • the solution is heated under reflux for 1h.
  • the solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide.
  • the dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness.
  • Step C 1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6] cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[4-(N-carboxamidopiperidinyl)]-4- piperidinecarboxamide
  • N-substituent CH 36.0, 128.2, 129.2, 127.0, 129.2, 128.2
  • the dichloromethane is removed in vacuo and anhydrous methanol (14.2ml) is added. The solution is heated under reflux for 1.25h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness.
  • N-substituent CH2 45.3/45.9, 28.9/29.1 , 29.5/30.2, 45.3/45.9, 41.7
  • Step B 1 -[1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin- 11 -yl)-4-[piperidinyl]-4-aminomethylpiperidine
  • Step B 1-(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 - yl)-3-piperidinecarboxylate
  • Step D Separation of Isomers
  • the compound of Example 10, Procedure 1 , Step C is separated into its four optical isomers by HPLC chromatography with a Chiralpak® AD analytical (0.46cmX25cm) chiral column (amylose tris(3,5-dimethylphenyl carbamate) coated on a 10 ⁇ M silica-gel substrate (trademark of of Chiral Technologies, Exton, Pennsylvania), using as the eluting solvent, 20% isopropanlol/ hexanes/.02% diethylamine at 1mL. minute, the four compounds elute at 10.27 (Isomer A), 11.43 (Isomer B), 11.57 (Isomer C) and 18.37 (Isomer D) minutes.
  • Step A L-Pipecolinic Acid Ethyl Ester Hydrochloride.
  • Step A D-Pipecolinic Acid Ethyl Ester Hydrochloride.
  • the product is chromatographed on a silica gel column using 1 % ethyl acetate- dichloromethane as the eluant to separate the two separable diastereomeric isomers (i.e. Isomers A1 ester and B1 ester), the less polar being referred to as Isomer A1 ester and the more polar isomer being referred to as Isomer B1 ester.
  • FABMS MH+ 464.
  • Step B (0.26g, 0.6 mmol) is dissolved in 6 mL of ethanol and 1.4 mL of 1 M LiOH (1.4 mmol) is added. The reaction mixture is heated on oil bath at 80°C for 10h, cooled and 1.5 mL of 1 N HCI is then added to adjust the pH to - 4.5. Solvents are then removed by evaporation and the resulting crude acid is used in the next reaction without further purification.
  • Example 14 Using the method of Examples 12 and 13, except that D- pipecolinic acid ethyl ester hydrochloride is used in place of L-pipecolinic acid ethyl ester hydrochloride, the following two diasteriomers are obtained:
  • Example 15 Using the method of Examples 12-14, except that in Example 12, Step D, 3-(aminomethyl)pyridine is used in place of 4-(aminomethyl)pyridine, the following four diasteriomers are prepared.
  • FPT IC50 0.3 ⁇ M
  • FPT IC 50 0.16 ⁇ M
  • the phenoxyimidate (1 equivalent) (prepared as described in Example 26 above) is dissolved in anhydrous THF. A 60% sodium hydride dispersion in oil 4 equivalents) is added and the mixture is stirred at 25°C for 2h. The mixture is diluted with dichloromethane and washed with 1 N sodium hydroxide. Chromatography on silica gel affords the title compound.
  • the phenoxyimidate (1 equivalent) (prepared as described in Example 26 above) is dissolved in concentrated ammonium hydroxide and ammonium chloride (1 equivalent) is added. The mixture is heated in a sealed tube at 90°C to give the title compound.
  • N-cyanophenoxyimidate (1 equivalent) (prepared as described in Example 27 above) is dissolved in concentrated ammonium hydroxide and the mixture is stirred at 25°C for 24h to give the title compound.
  • N-sulfamoylphenoxyimidate (1 equivalent) (prepared as described in Example 28 above) is dissolved in concentrated ammonium hydroxide and the mixture is stirred at 25°C for 24h to give the title compound.
  • the phenoxyimidate (1 equivalent) (prepared as described in Example 26 above) is dissolved in methanol.
  • An aqueous solution of methoxylamine (1 equivalent) [prepared by dissolving methoxylamine hydrochloride (1 equivalent) in 50% (w/v) sodium hydroxide (1 equivalent)] is added and the mixture is stirred at 25°C to give the title compound.
  • Benzanilide is converted into the choloroimidate (as described in: A. C. Honz and E. C. Wagner, Org. Syn. Coll. Vol. 4, 383-386 (1963) (1.1 equivalents) and this is reacted with 1 -(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 -yl)-N-(4-piper idinylmethyl)-4- piperidine-carboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in pyridine at reflux temperature to give the title compound.
  • the solution is diluted with dichloromethane and washed with 1 N NaOH , dried over magnesium sulfate, filtered and evaporated to dryness.
  • the product is chromatographed on silica gel using 4% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.219g, 44%), SIMS: m/z 539 (MH+), FPT INH 43% @ 0.22 ⁇ M.
  • Example 44 1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyr idin-11 -yl)-N-(3-pyridylmethyl)-4-piperidinepropanamide
  • Step A 4-[1-(8-Chloro-3,10-dibromo-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-4-piperidineacetyl]-1 -N-tert -butoxycarbonylpiperazine
  • Step B 1-[1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 -yl)-4-piperidineacetyl]piperazine
  • Step C 4-[1 -(8-Chloro-3, 10-dibromo-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11 -yl)-4-piperidineacetyl]-1 -piperazinecarboxamide
  • Example 50 1 -(3, 10-Dibromo-8-chloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-methyl-3-piperidinecarboxamide
  • Example 53 1-(3,10-Dibromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[[1 -[(dimethylamino)acetyl]-4- piperidinyl]methyl]-3-piperidinecarboxamide
  • Example 54 1-(3,10-Dibromo-8-chloro-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[3-(2-oxo-1 -pyrrolidinyl)propyl]-3- piperidinecarboxamide
  • the 2-, 3- or 4-substituted pyridine compound can subsequently be reduced using conventional reduction procedures, such as catalytic hydrogenation, to give the desired piperidinyl compound (7.0).
  • One skilled in the art will appreciate that in cases where -R 5 , -R 6 , -R 7 , -R 8 and/ or Z moieties also contain reducible groups, it may useful to utilize alternative methods.
  • a suitable chlorinating agent such as thionyl chloride
  • N-blocking groups such as benzyloxycarbonyl or tert-butoxycar bonyl.
  • the 2-,3-, or 4-chloro-N-blocked piperidine can then be reacted with sodium bisulfite
  • This salt is then reacted with an appropriate chlorinating agent such as phosphorus pentachloride or phosphorus oxychloride to obtain the corresponding 2-, 3- or 4-sulfonylchloride-N-blocked piperidine.
  • This sulfonyl chloride is then reacted with the corresponding agent containing the desired Z group (i.e. amines, alkylating agents and the like) to obtain the desired sulfonylpiperidine (7.0).
  • the 2-, 3-, or 4-chloro-N- blocked piperidine can then reacted with the corresponding substituted sulfide (i.e.
  • Isonipecotic acid (5g; 1 equivalent) is dissolved in water (50 ml) and a solution of di-tert -butyldicarbonate (8.62g; 1.02 equivalents) in THF (70 ml) is added with stirring. The mixture is stirred at 80°C for 2 h and then evaporated to dryness. The residue is partitioned between dichloromethane and brine and the dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness.
  • 1-N-(terf -Butoxycarbonyl)-4-piperidinecarboxylic acid (1.218; 1 equivalent) (prepared as described in Step A above), DEC (1.0184g; 1 equivalent), HOBT (0.7179g; 1 equivalent) and N-methylmorpholine (0.5841ml; 1 equivalent) are dissolved in anhydrous DMF (30 ml) and the mixture is stirred under argon at 25°C for 19 h. The solution is evaporated to dryness. The residue is taken up in dichloromethane and washed with water. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness.
  • Step C 4-Piperidinyl-N-(4-pyridinyl)carboxamide
  • Step C 4-(Aminomethyl)-1-N-(ter_ -butoxycarbonyl)piperidine
  • Step B 1 -N-Benzyl-4-(aminomethyl)piperidine
  • 1-N-Benzyl-4-piperidinecarboxamide (1g; 1 equivalent) (prepared as described in Step A above) is dissolved in anhydrous THF (25ml).
  • Lithium aluminum hydride (0.2173g) (1.25 equivalents) in anhydrous THF (5.726ml) is added dropwise over 0.5h and the mixture is heated under reflux under nitrogen for 20h.
  • the mixture is cooled and diluted with dichloromethane (750ml) and washed with 1.0N sodium hydroxide.
  • the dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness.
  • Benzyloxycarbonylimidazole (1.7709g; 1 equivalent) [prepared as described in: S. K. Sharma, M. J. Miller and S. M. Payne, J. Med. Chem., 32, 357-367 (1989)] is added and the mixture is stirred at 25°C for 23 h.
  • the solution is diluted with dichloromethane and washed with 1.0N sodium hydroxide.
  • the dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness.
  • Step B 1 -N-(Benzyloxycarbonyl)-4-[N-(terf -butoxycarbonyl)aminomethyl]piperidine
  • 4-(N-Benzyloxycarbonylaminomethyl)piperidine (0.6814g; 1 equivalent) (prepared as described in Step A above) is dissolved in anhydrous toluene (5 ml) and di-tert -butyldicarbonate (0.599g; 1 equivalent) in anhydrous toluene (5 ml) is added dropwise. The mixture is stirred at 0°C for 2h and at 25°C for 20 h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.0N sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness.
  • Step C 4-[(tert -Butoxycarbonylamino)methyI]piperidine
  • Step F Combine 8.6 g (21.4 mmol) of the product of Step D and 300 mL of MeOH and cool to 0°-2°C. Add 1.21 g (32.1 mmol) of NaBH4 and stir the mixture at ⁇ 0°C for 1 hr. Add another 0.121 g (3.21 mmol) of NaBH4, stir for 2 hr. at 0°C, then let stand overnight at 0°C. Concentrate in vacuo to a residue then partition the residue between CH2CI2 and water. Separate the organic phase and concentrate in vacuo (50°C) to give 8.2 g of the product.
  • Step F 3, 10-dibromo-8, 11 -dichloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine
  • Step A -tert -butoxycarbonyl-N-(3-pyridylmethyl)-4-piperidineacetamide
  • 3-(4-Pyridyl)acrylic acid (2g, 13.4mmoles) is dissolved in water (70ml) and concentrated hydrochloric acid (1 ml). 10% Pd-C (1.5 spatulas) is added and the mixture is hydrogenated at 25°C at 55psi for 72h. The mixture is filtered through Celite® and then passed over a bed of Bio Rad AG 1 -X8 (OH”) resin. The resin is washed with water and the combined eluates are evaporated to dryness to give the title compound that is used in Step B without further purification.
  • Step B x -tert -Butoxycarbonyl-4-piperidinepropionic acid
  • N-(3-Pyridylmethyl)-1 -tert -butoxycarbonyl-4-piperidinepropanamide (2.222g, 6.4mmoles) is dissolved in methanol (38.15ml) and 10% cone. H2SO4 in dioxane (v/v) (95.38ml) is added and the mixture is stirred under argon at 25°C for 1.5h. The volume is reduced to half and the mixture is basified to pH 12 with 50% NaOH aq and extracted with dichloromethane. The latter is dried over magnesium sulfate, filtered and evaporated to dryness.
  • 1-tert -Butoxycarbonyl-4-piperidineacetic acid (1g, 4.1mmoles) (prepared as described in Preparative Example 17, Step C in IN0291K), ethanol (200 proof) (0.284g, 0.362ml, 6.2mmoles), DEC.HCI (1.18g, 6.2mmoles), HOBT (0.8331 g, 6.2mmoles) and NMM (0.624g, 0.678ml, 6.2mmoles) are dissolved in anhydrous DMF (30ml) and the mixture is stirred at 25°C under argon for 24h.
  • Ethyl 1-fert -butoxycarbonyl-4-piperidineacetate (0.6g, 2.2mmoles) is dissolved in ethanol (30ml) and 10% cone. H2SO4 in dioxane (v/v) (30ml) is added and the mixture is stirred at 25°C for 2h. The mixture is passed over a bed of Bio Rad AG1-X8 (OH') resin and the resin is then eluted with ethanol. The combined eluates are evaporated to dryness and the residue is chromatographed on silica gel using 1% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound.
  • Ethyl 1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11-yl)-4-piperidineacetate (0.3g, 0.5mmoles) (prepared as described in Step A above) is dissolved in ethanol (4ml) and dichloromethane (4ml) and 1 M lithium hydroxide in water (1.21mmoles) is added. The mixture is stirred at 50°C for 5h. 1N Hydrochloric acid (1.21mmoles) is added and the solution is evaporated to dryness to give the title compound which is used without further purification.
  • FPT IC50 inhibition of farnesyl protein transferase, in vitro enzyme assay
  • COS IC50 values refer to the COS cells activity inhibition of Ras processing, are determined by the methods disclosed in WO/10515 or WO 95/10516.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 70 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transder mally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compound is administered orally.
  • the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 300 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
  • a typical recommended dosage regimen is oral administration of from 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to block tumor growth.
  • the compounds are non-toxic when administered within this dosage range.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR9, wherein R9 is O-, -CH¿3? or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR?1 or CR2¿; or each of a, b, c and d is independently selected from CR?1 or CR2¿; each R1 and each R2 is independently selected from H, halo, -CR¿3?, -OR?10, -COR10, -SR10¿, -S(O)¿tR?11 (wherein t is 0, 1 or 2), -SCN, -N(R10)2, -NR?10R11, -NO¿2, -OC(O)R10, -CO2R10, -OCO¿2R?11, -CN, -NHC(O)R10, -NHSO¿2R?10, -CONHR10, -CONHCH¿2?CH2OH, -NR?10COOR11, -SR11C(O)OR11, -SR11N(R75)2¿; n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO¿2?-; or -CR?30R31¿-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR?40, -SR40, -CR40R42, -NR40R42¿, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.

Description

NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
BACKGROUND
Patent application WO 95/00497 published 5 January 1995 under the Patent Cooperation Treaty (PCT) describes compounds which inhibit the enzyme, famesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis. Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non- transformed cells. Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer.
To acquire transforming potential, the precursor of the Ras oncoprotein must undergo farnesylation of the cysteine residue located in a carboxyl- terminal tetrapeptide. Inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase, have therefore been suggested as anticancer agents for tumors in which Ras contributes to transformation. Mutated, oncogenic forms of Ras are frequently found in many human cancers, most notably in more than 50% of colon and pancreatic carcinomas (Kohl et al., Science, Vol. 260, 1834 to 1837, 1993). In view of the current interest in inhibitors of farnesyl protein transferase, a welcome contribution to the art would be additional compounds useful for the inhibition of farnesyl protein transferase. Such a contribution is provided by this invention.
SUMMARY OF THE INVENTION
Inhibition of farnesyl protein transferase by tricyclic compounds of this invention has not been reported previously. Thus, this invention provides a method for inhibiting farnesyl protein transferase using tricyclic compounds of this invention which: (i) potently inhibit farnesyl protein transferase, but not geranylgeranyl protein transferase I, in vitro: (ii) block the phenotypic change induced by a form of transforming Ras which is a farnesyl acceptor but not by a form of transforming Ras engineered to be a geranylgeranyl acceptor; (iii) block intracellular processing of Ras which is a farnesyl acceptor but not of Ras engineered to be a geranylgeranyl acceptor; and (iv) block abnormal cell growth in culture induced by transforming Ras. Several compounds of this invention have been demonstrated to have anti-tumor activity in animal models.
This invention provides a method for inhibiting the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of this invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.
Compounds useful in the claimed methods are represented by Formula 1.0:
Figure imgf000004_0001
or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c and d represents N or NR9 wherein R9 is O", -CH3 or -(CH2)nC02H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR1 or CR2; or each of a, b, c, and d are independently selected from CR1 or CR2; each R1 and each R2 is independently selected from H, halo, -CF3, -OR10, -COR10, -SR10, -S(0)tR11 (wherein t is 0, 1 or 2), -SCN, -N(R10)2, -NR 0R1 1 , -N02, -OC(0)R1°, -C02R10, -OC02R11, -CN, -NHC(0)R10, -NHS02R1°, -CONHR10, -CONHCH2CH2OH, -NR1°COOR1 1 , -SR1 1C(0)OR1 , -SR1 1N(R75)2 wherein each R75 is independently selected from H and -C(0)OR11, benzotriazol-1-yloxy, tetrazol-5-ylthio, or substituted tetrazol-5- ylthio, alkynyl, alkenyl or alkyl, said alkyl or alkenyl group optionally being substituted with halo, -OR10 or -CO2R10;
R3 and R4 are the same or different and each independently represents H, any of the substituents of R1 and R2, or R3 and R4 taken together represent a saturated or unsaturated C5-C7 fused ring to the benzene ring (Ring III);
R5, R6, R7 and R8 each independently represents H, -CF3, -COR10, alkyl or aryl, said alkyl or aryl optionally being substituted with -OR10, -SR10, -S(0)tR1 1 , -NR10COOR1 1 , -N(R10)2, -N02, -COR10, -OCOR10, -OC02R11 , -CO2R10, OPO3R10, or R5 is combined with R6 to represent =0 or =S and/or R7 is combined with R8 to represent =0 or =S;
R10 represents H, alkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, aryl, aralkyl or -NR40R42 wherein R40 and R42 independently represent H, aryl, alkyl, aralkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl;
R1 1 represents alkyl or aryl; the dotted line between carbon atoms 5 and 6 represents an optional double bond, such that when a double bond is present, A and B independently represent -N02, -R10, halo, -OR1 1 , -OCO2R11 or -OC(0)R1°, and when no double bond is present between carbon atoms 5 and 6, A and B each independently represent H2, -(0R11)2, H and halo, dihalo, alkyl and H, (alkyl)2, -H and -OC(0)R10, H and -OR10, oxy, aryl and H, =NOR10 or -O- (CH2)p-0- wherein p is 2, 3 or 4; n is 0 (zero), 1 , 2, 3, 4, 5 or 6;
T is -CO-; -SO-; -S0 -; or -CR30R31- wherein R30 and R31 independently represent H, alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; and Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR40, -SR40, -CR40R42, -NR40R42,
ls
Figure imgf000005_0001
i-(CH2)q-NR 144 DR40
Figure imgf000005_0002
wherein n, R40 and R42 are defined hereinbefore, m is 2, 34, 5, 6, 7 or 8; q is 0 (zero), 1 or 2; and R14 represents H, Cι.6 alkyl, aralkyl, heteroaryl, acyl, carboxamido, carboxamidoalkyl, cyano, alkoxycarbonyl, aralkyloxycarbonyl, D- and L-amino acids covalβntly bonded through the carboxyl group, imido, imidamido, sulfamoyl, sulfonyl, dialkylphosphinyl, N-glycosyl,
Figure imgf000006_0001
CR 6Hπ5
Figure imgf000006_0002
-C(NHCH3)=CHN02l with the proviso that when T is -SO-, Z is not -NR40R42.
In the compounds of formula (1.0), preferably a is N; b, c and d are carbon; A and B each represent H2 and the optional double bond is absent. Also preferred is that R1 and R4 are H and R2 and R3 are halo selected from chloro and bromo; or R1 is H and R2, R3 and R4 are halo selected from chloro and bromo. Also preferred is that R2 and R3 are halo in the 3- and the 8-position on the ring structure; or R2, R3 and R4 are in the 3-, 8- and 10- position on the ring structure. Also preferred is that R2 is Br and R3 is Cl in the 3- and the 8-position on the ring structure; or R2 is Br, R3 is Cl and R4 is Br in the 3-, 8- and 10- position on the ring structure. Also preferred is that each of R5, R6, R7 and R8 is H. Also preferred is that the moiety -(CH2)n-T-Z is bonded at the 2-, 3- or 4-position on the piperdinyl ring, more preferably at the 2- or 3- position on the piperdinyl ring.
Also preferred in the compounds of formula (1.0) is that n is zero, 1 or 2; T is -CO- and Z is -NR40R42 wherein R40 and R42 independently represent H, aryl, alkyl, aralkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroalkyl, cycloalkyl or cycloalkylalkyl; or Z is
Figure imgf000007_0001
wherein R40 is defined hereinbefore, m is 2, 3 or 4; q is O (zero), 1 or 2; and R14 represents H, Ci .6 alkyl, aralkyl, heteroaryl, acyl, carboxamido, carboxamidoalkyl, cyano, alkoxycarbonyl, aralkyloxycarbonyl imido, imidamido, sulfamoyl, sulfonyl, dialkylphosphinyl, N-glycosyl or-C(NHCH3)=CHN02- More preferably, n is zero; Z is -NR40R42 wherein R40 represents H and R42 represents heteroarylalkyl. More preferably R40 is H and R42 is the heteroaryl moiety 3-pyridylmethyl.
In another embodiment, the present invention is directed toward a pharmaceutical composition for inhibiting the abnormal growth of cells comprising an effective amount of compound (1.0) in combination with a pharmaceutically acceptable carrier.
In another embodiment, the present invention is directed toward a method for inhibiting the abnormal growth of cells, including transformed cells, comprising administering an effective amount of compound (1.0) to a mammal (e.g., a human) in need of such treatment. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs, and (4) benign or malignant cells that are activated by mechanisms other than the Ras protein. Without wishing to be bound by theory, it is believed that these compounds may function either through the inhibition of G-protein function, such as ras p21 , by blocking G-protein isoprenyiation, thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer, or through inhibition of ras farnesyl protein transferase, thus making them useful for their antiproliferative activity against ras transformed cells. The cells to be inhibited can be tumor cells expressing an activated ras oncogene. For example, the types of cells that may be inhibited include pancreatic tumor cells, lung cancer cells, myeloid leukemia tumor cells, thyroid follicular tumor cells, myelodysplastic tumor cells, epidermal carcinoma tumor cells, bladder carcinoma tumor cells or colon tumors cells. Also, the inhibition of the abnormal growth of cells by the treatment with compound (1.0) may be by inhibiting ras farnesyl protein transferase. The inhibition may be of tumor cells wherein the Ras protein is activated as a result of oncogenic mutation in genes other than the Ras gene. Alternatively, compounds (1.0) may inhibit tumor cells activated by a protein other than the Ras protein.
This invention also provides a method for inhibiting tumor growth by administering an effective amount of compound (1.0) to a mammal (e.g., a human) in need of such treatment. In particular, this invention provides a method for inhibiting the growth of tumors expressing an activated Ras oncogene by the administration of an effective amount of the above described compounds. Examples of tumors which may be inhibited include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma and epidermal carcinoma.
It is believed that this invention also provides a method for inhibiting proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes-i.e., the Ras gene itself is not activated by mutation to an oncogenic form-with said inhibition being accomplished by the administration of an effective amount of the carbonyl piperazinyl and piperidinyl compounds (1.0) described herein, to a mammal (e.g., a human) in need of such treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes (e.g., neu, src, abl, lck, and fyn), may be inhibited by the carbonyl piperazinyl and piperidinyl compounds (1.0) described herein. In another embodiment, the present invention is directed toward a method for inhibiting ras farnesyl protein transferase and the farnesylation of the oncogene protein Ras by administering an effective amount of compound (1.0) to mammals, especially humans. The administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase, is useful in the treatment of the cancers described above.
DETAILED DESCRIPTION OF THE INVENTION The following solvents and reagents are referred to herein by the abbreviations indicated: tetrahydrofuran (THF); ethanol (EtOH); methanol (MeOH); ethyl acetate (EtOAc); N,N-dimethylformamide (DMF); trifluoroacetic acid (TFA); 1 -hydroxybenzotriazole (HOBT);
1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (DEC); dimethylsulfoxide (DMSO); 4-methylmopholine (NMM); dimethylaminopyridine (DMAP); and dimethoxyethane (DME). t-butoxycarbonyl (BOC) acetyl(OAc)
As used herein, the following terms are used as defined below unless otherwise indicated:
or - indicates a pure isomer;
- when attached to a carbon atom labeled with an asterisk (*), indicates a separated isomer whose stereochemistry is not established;
- indicates a racemic mixture;
M+ -represents the molecular ion of the molecule in the mass spectrum;
MH+ -represents the molecular ion plus hydrogen of the molecule in the mass spectrum;
Bu-represents butyl;
Et-represents ethyl;
Me-represents methyl;
Ph-represents phenyl; benzotriazol-1-yloxy represents
Figure imgf000010_0001
1 -methyl-tetrazol-5-ylthio represents
Figure imgf000010_0002
acyl-a moiety of the formula -COR15 wherein R15 represents H, C-i -6alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl or -(CH2)_NR80R81 wherein k is 1 or 2, and R80 and R81 may independently represent H, alkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl or aralkyl; alkyl-(including the alkyl portions of alkoxy, alkylamino and dialkylamino)-represents straight and branched carbon chains and contains from one to twenty carbon atoms, preferably one to six carbon atoms (i.e. C-ι-6 alkyl); for example methyl, ethyl, propyl, iso-propyl, n-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; wherein said alkyl and said C-ι-6 alkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino (-NH2), alkylamino, cyano (- CN), -CF3, dialkylamino, hydroxy, oxy (=0), phenoxy, -OCF3, heterocycloalkyl, -S02NH2. -NHSO2R10, -SO2NHR10, -S02R1°, -SOR10, -SR10, -NHSO2, -NO2, -NCOR10 or -COOR10. alkoxy-an alkyl moiety of one to 20 carbon atoms covalently bonded to an adjacent structural element through an oxygen atom, for example, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like; wherein said alkoxy group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -SO2NH2, -NHSO2R10, -SO2NHR10, -S0 R10, -SOR10, -SR10, -NHSO2, -N02, -CONR10, -NCOR10 or -COOR10; alkoxycarbonyl - represents a alkoxy moiety, as defined above, covalantly bonded to a carbonyl moiety (-CO-) through an oxygen atom, for example, -COOCH3, -COOCH2CH3 and -COOC(CH3)3; alkenyl-represents straight and branched carbon chains having at least one carbon to carbon double bond and containing from 2 to 12 carbon atoms, preferably from 2 to 6 carbon atoms and most preferably from 3 to 6 carbon atoms; wherein said alkenyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -S02NH2, -NHS02R1°, -S02NHR1°, -S02R10, -SOR10, -SR10, -NHSO2, -N02, -CONR10, -NCOR10 or -COOR10; alkynyl-represents straight and branched carbon chains having at least one carbon to carbon triple bond and containing from 2 to 12 carbon atoms, preferably from 2 to 6 carbon atoms; wherein said alkynyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -SO2NH2, -NHSO2R10, -SO2NHR10, -S02R10, -SOR10, -SR1 -NHSO2, -N02, -CONR10, -NCOR10 or -COOR10; amino acid- refers to organic compounds having both an amino group (-NH2) and a carboxyl group (-COOH). Representative amino acids include glycine, serine, alanine, phenylalanine, tyrosine, S-methyl methionine and histidine; aryl (including the aryl portion of aralkyl)-represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is phenyl), wherein said aryl group optionally can be fused with aryl, cycloalkyl, heteroaryl or heterocycloalkyl rings; and wherein any of the available substitutable carbon and nitrogen atoms in said aryl group and/or said fused ring(s) may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -S02NH2, -NHSO2R10, -SO2NHR10, -S02R1°, -SOR10, -SR10, -NHSO2, -N0 , -CONR10, -NCOR10 or -COOR10; aralkyl - represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety have been substituted with one or more aryl groups; wherein said aralkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -S02NH2) -NHS02R1°, -S02NHR1° -S02R10, -SOR10, -SR10, -NHSO2, -N02, -CONR10, -NCOR10 or -COOR10; Representative aralkyl groups include benzyl and diphenylmethyl; aralkyloxy - represents an aralkyl group, as defined above, covalently bonded to an adjacent structural element through an oxygen atom, for example, phenylmethyloxy and phenylethyloxy; aralkyloxycarbonyl - represents an aralkyloxy group, as defined above, covalantly bonded to a carbonyl moiety (-CO-) through an oxygen atom, for example, -COOCH2C6H5 and -COOCH2CH2C6H5; carboxamido - represents a moiety of the formula -CONR40R42, including -CONH ; carboxamidoalkyl - represents an alkyl group, as defined above, wherein a hydrogen atom of the alkyl moiety has been substituted with a carboxamido moiety, as defined above, through the carbonyl (-CO) portion of the carboxamido moiety, for example, -CH2CONH2 and -CH2CH2CONH2; cycloalkyl-represents saturated carbocyclic rings branched or unbranched of from 3 to 20 carbon atoms, preferably 3 to 7 carbon atoms; wherein said cycloalkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3l heterocycloalkyl, -S02NH2, -NHS02R10, -S02NHR1°, -S02R1°, -SOR10, -SR10, -NHS02, -N02, -CONR10, -NCOR10 or -COOR10; cycloalkylalkyl - represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety have been substituted with one or more cycloalkyl groups; wherein said cycloalkylalkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -S02NH2, -NHSO2R10, -SO2NHR10, -S02R1°, -SOR10, -SR10, -NHSO2, -N02, -CONR10, -NCOR10 or -COOR10; halo-represents fluoro, chloro, bromo and iodo; heteroalkyl-represents straight and branched carbon chains containing from one to twenty carbon atoms, preferably one to six carbon atoms interrupted by 1 to 3 heteroatoms selected from -O-, -S- and -N-; wherein any of the available substitutable carbon and nitrogen atoms in said heteroalkyl chain may be optionally and independendently substituted with one, two, three or more of the following: halo, C-i-Ce alkyl, aryl, cyano, hydroxy, alkoxy, oxy, phenoxy, -CF3, -OCF3, amino, alkylamino, dialkylamino, heterocycloalkyl, -S02NH2, -NHS02R1°, -SO2NHR10, -S02R10, -SOR10, -SR10, or -NHS02, -N02, -CONR10, -NCOR10 or -COOR10; heteroaryl-represents cyclic groups having at least one heteroatom selected from O, S and N, said heteroatom(s) interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic groups containing from 2 to 14 carbon atoms.wherein said heteroaryl group optionally can be fused with one or more aryl, cycloalkyl, heteroaryl or heterocycloalkyl rings; and wherein any of the available substitutable carbon or nitrogen atoms in said heteroaryl group and/or said fused ring(s) may be optionally and independendently substituted with one, two, three or more of the following: halo, C-i-Cβ alkyl, aryl, cyano, hydroxy, alkoxy, oxy, phenoxy, -CF3, -OCF3, amino, alkylamino, dialkylamino, heterocycloalkyl, -S02NH2, -NHS02R1°, -S02NHR °, -S02R1°, -SOR10, -SR10, or -NHSO2, -N02) -CONR10, -NCOR10 or -COOR10. Representative heteroaryl groups can include, for example, furanyl, imidazoyl, pyrimidinyl, triazolyl, 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl N-oxide wherein pyridyl N-oxide can be represented as:
Figure imgf000013_0001
heteroarylalkyl - represents an alkyl group, as defined above, wherein one or more hydrogen atoms have been replaced by one or more heteroaryl groups; wherein said heteroarylalkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -S02NH2, -NHSO2R10, -S02NHR1°, -S02R10, -SOR10, -SR10, -NHSO2, -N02, -CONR10, -NCOR10 or -COOR10; as exemplified by 2-, 3- or 4-pyr idylmethyl or 2-, 3- or 4-pyridylmethyl N-oxide; heterocycloalkyl-represents a saturated, branched or unbranched carbocylic ring containing from 3 to 15 carbon atoms, preferably from 4 to 6 carbon atoms, which carbocyclic ring is interrupted by 1 to 3 heteroatoms selected from -0-, -S- and -N- , wherein optionally, said ring may contain one or two unsaturated bonds which do not impart aromatic character to the ring; and wherein any of the available substitutable carbon and nitrogen atoms in the ring may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -SO2NH2, -NHS02R10, -SO2NHR10, -S02R10, -SOR10, -SR10, -NHS02, -N02, -CONR10, -NCOR10 or -COOR10
Representative heterocycloalkyl groups can include morpholinyl, 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 1-, 2-, 3- or 4-piperidinyl, 2- or 3- — N S(O), pyrrolidinyl, 1-, 2- or 3-piperizinyl, 2- or 4-dioxanyl, or wherein t is 0, 1 or 2; heterocycloalkylalkyl- represents an alkyl group, as defined above, wherein one or more hydrogen atoms have been replaced by one or more heterocycloalkyl groups; wherein optionally, said ring may contain one or two unsaturated bonds which do not impart aromatic character to the ring; and wherein said heterocycloalkylalkyl group may be optionally and independently substituted with one, two, three or more of the following: halo, alkyl, aryl, alkoxy, amino, alkylamino, cyano, -CF3, dialkylamino, hydroxy, oxy, phenoxy, -OCF3, heterocycloalkyl, -S02NH2, -NHS02R10, -S02NHR10, -S02R10, -SOR10, -SR10, -NHS02, -N02, -CONR10, -NCOR10 or -COOR10; imido - represents a moiety of the formula
Figure imgf000014_0001
wherein and R50 represents H, cyano, aryl, -Sθ2 H2,
-SO2NR40R42 and carboxamido and R51 represents aryl and aryloxy. Representative imido groups can include, for example,
Figure imgf000014_0002
imidamido - represents a moiety of the formula
Figure imgf000014_0003
wherein and R55 represents H, cyano, -Sθ2NH2, -SO2NR40R42, carboxamido, hydroxy and alkoxy. Representative imidamido groups can include, for example,
Figure imgf000015_0001
N-glycosyl- represents a pyranosyl or furanosyl monosaccaride. Representative N-glycosyl groups include (N — *■ 1)-tetra-0-acetyl-D-glucosyl, (N -*■ 1)-tetra-0-acetyl-D-galactosyl and (N -*" 1) -tri-O-acetyl-D-ribosyl, e.g.
Figure imgf000015_0002
D-glycosyl D-galactosyl D-ribosyl
1-amino-2-nitroethenyl represents the formula: -C(NHCH3)=CHNC>2; dialkylphosphinyl - represents a phosphine (-PO) moiety covalently bonded to two alkyl groups. A representative dialkylphosphinyl group is
-PO(CH3) . sulfamoyl - represents a moiety of the formula -SO2R60 wherein R60 represents amino, alkylamino and dialkylamino. Representative sulfamoyl groups can include, for example, -S02NH2, -SO2NHCH3, -S0 N(CH3)2. sulfonyl - represents a moiety of the formula -SO2R60 wherein R60 represents alkyl, aryl and arylalkyl. Representative sulfonyl groups can include, for example, -S0 CH3, -Sθ2C6H5, -S02C6H4CH3, and
-SO2CH2C6H5.
Reference to the position of the substituents R1, R2, R3, and R4 is based on the numbered ring structure:
Figure imgf000016_0001
Certain compounds of the invention may exist in different stereoisomeric forms (e.g., isomers such as enantiomers and diastereoisomers). The invention contemplates all such stereoisomers both in pure form and in mixture, including racemic mixtures. For example, the carbon atom at the C-11 position can be in the S or R stereoconfiguration. Also, the carbon atom at the C-2, C-3, C-5 and C-6 positions of the piperidinyl moiety bonded at C-11 can also be in the S or R stereoconfiguration. Certain tricyclic compounds will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N- methylglucamine and the like.
Certain basic tricyclic compounds also form pharmaceutically acceptable salts, e.g., acid addition salts. For example, the pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention. All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Compounds of the present invention can be prepared according to the following Scheme I:
Scheme 1
Figure imgf000018_0001
wherein L represents a leaving group such as halo, preferably chloro or a leaving group such as o-tosyl and o-mesyl; the dotted line represents a single or double bond; and a, b, c, d, A, B, R1 , R2, R3, R4, R5, R6, R7, R8, n, T and Z are as defined hereinbefore. Referring to the Scheme I, compounds of formula (5.0) can be prepared by reacting the compounds of formula (3.0) with a halogenating agent or a sulfonylating agent in the presence of a suitable base, and optional aprotic solvent, in amounts and under conditions effective to give compounds (5.0). Suitable bases include organic bases such as pyridine and triethylamine; or inorganic bases of alkali and alkaline earth metals including carbonates such as sodium, lithium, potassium and cesium carbonates, hydroxides such as sodium, lithium and potassium hydroxides; hydrides such as sodium or potassium hydride; and sodium t-butoxide, preferably sodium hydride. Suitable aprotic solvents include ethers, DMF, DMSO, THF, DME and mixtures thereof, preferably DMF. Preferably the halogenating agent is a chlorinating agent, such as thionyl chloride. The sulfonylating can be methane sulfonyl chloride or toluene sulfonyl chloride. The amounts of the halogenating agent or the sulfonylating agent can range from about one to about 10 moles per mole of compound (3.0). Temperatures can range from 0° to 50°C, or reflux of the reaction mixture.
The desired tricylic piperidinyl compounds of formula (1.0) can be prepared by reacting the compounds of formula (5.0) with a suitably substituted piperidinyl compound of formula (7.0) in the presence of a suitable base and optional aprotic solvent, such as those described above, to give compounds (1.0). The amounts of the substituted piperidinyl compound of formula (7.0) to compound (5.0) can range from about one to about 10 moles per mole of compound (5.0) Temperatures can range from about room temperature to about 80°C.
The tricylic piperidinyl compounds of fomula (1.0) can be isolated from the reaction mixture using conventional procedures, such as, for example, extraction of the reaction mixture from water with organic solvents, evaporation of the organic solvents, followed by chromatography on silica gel or other suitable chromatographic media.
Selected compounds of formula (1.0) can be prepared in accordance with Scheme 2.
Scheme 2
Figure imgf000020_0001
wherein L represents a leaving group, preferably chloro; the dotted line represents a single or double bond; and a, b, c, d, A, B, R1 , R2, R3, R4, R5, R6, R7, R8, R8, R11, R40, R42 and n are as defined hereinbefore.
Referring to the Scheme 2, compounds of formula (8.0) can be prepared by reacting the compounds of formula (5.0) with a piperdinyl carboxylic acid ester of formula (7.5 ) in the presence of a base and optional aprotic solvent, in amounts and under conditions effective to give compounds (8.0). Suitable bases and aprotic solvents are described hereinbefore. The amounts of piperidinyl compound (7.5) can range from about 1 to about 10 moles per mole of compound (5.0). Temperatures can range from room temperature to about 80°C. Compound (8.0) can be isolated as described hereinbefore.
Carboxylic acid compounds of formula (8.5) can be prepared by hydrolyzing carboxylic acid ester (8.0) with an excess amount of acid or base. Suitable acids include inorganic acids, organic acids or a mixture thereof. Inorganic acids include hydrogen chloride, hydrogen bromide, sulfuric acid, nitric acid, phosphoric acid, perchloric acid and the like. Organic acids include acetic, citric, formic, maleic, tartaric, methanesulfonic acid and arylsulfonic acids. Suitable bases, such as sodium hydroxide or lithium hydroxide, preferably in an aqueous alcohol, have been described hereinbefore. The temperature can range from about 0°C to about 100°C. The desired amide compounds of formula (1.1) can be prepared by reacting the compounds of formula (8.5) with a suitable amine of formula (9.0) in the presence of a coupling agent such as DEC/HOBT, a base such as NMM and a suitable aprotic solvent effective to give amide compound (1.1 ). Suitable bases and aprotic solvents are described hereinbefore. The amounts of amine (9.0) can range from about 1 to about 10 moles per mole of carboxylic acid (8.5). Temperatures can range from 0° to 100°C. Compound (1.1 ) can be isolated as described hereinbefore.
Compounds of the present invention and preparative starting materials therof, are exemplified by the following examples, which should not be construed as limiting the scope of the disclosure.
EXAMPLE 1. 1-[8-Chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 -yl]-N-(4-pyridinyl)-4-piperidinecarboxamide
Figure imgf000021_0001
8,11 -Dichloro-6, 1 1 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridine (prepared as described in Preparative Example 7, Step B in IN0291K) (0.088g; 1 equivalent) in anhydrous toluene (0.819 ml) is added to anhydrous DMSO (1.5ml). 4-Piperidinyl-N-(4-pyridinyl)carboxmide (0.0684g; 1 equivalent) (prepared as described in Preparative Example 1 , Step C below) is added and the mixture is stirred at 25°C for 22h. The mixture is diluted with dichloromethane and washed with water. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (15X2.5cm) using 1% increasing to 8% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.0272g; 19% yield), CIMS: m/z 433 (MH+). FPT IC50 = 9.24 μM δc (CDCI3)
Tricyclic CH2: 30.4, 30.2
CH: 146.1 , 139.5, 130.9,123.4, 126.1 , 132.4, 80.2
C: 141.3, 135.2, 136.7, 134.0, 158.1
Piperidine CH2: 29.0, 51.4, 51.2, 28.7
CH: 44.3
C: 175.3
Piperidine CH: 150.6, 113.9, 113.9, 150.6 N-substituent C: 146.1
EXAMPLE 2. 1 -(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(4-pyridinyl)-4- piperidinecarboxamide
Figure imgf000022_0001
1 -[3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl]-4-piperidinecarboxylate (0.25g) (1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (9ml) is added to a solution of 4-aminopyridine (0.0761 g) (1.5 equivalents), DEC (0.155g) (1.5 equivalents), HOBT (0.1093g) (1.5 equivalents) and N-methylmorpholine (0.0889ml) (1.5 equivalents) in anhydrous DMF (4ml) and the mixture is stirred at 25°C for 42h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 1.5% increasing to 3% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.0308g; 12%), CIMS: m/z 511 (MH+). FPT Inhibition = 0% @ 0.39 μM δc (CDCI3)
Tricyclic CH2: 30.4, 29.9
CH: 146.9, 141.3, 132.2, 126.1 , 130.5, 79.4
C: 119.8, 140.7, 134.0, 136.1 , 136.7, 156.5
Piperidine CH2: 29.0, 51.2, 51.5, 30.4
CH: 44.5
C: 174.6
Piperidine CH: 150.5, 113.8, 113.8, 150.5 N-substituent C: 145.9
EXAMPLE 3. 1-(3-Bromo-8-chloro-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-1 1 -yl)-N-(4-pyridinylmethyl)-4- piperidinecarboxamide
Figure imgf000023_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-4-piperidinecarboxylate (0.25g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (9ml) is added to a solution of 4-aminomethylpyridine (0.0821ml; 1.5 equivalents), DEC (0.155g; 1.5 equivalents), HOBT (0.1093g; 1.5 equivalents) and N- methylmorpholine (0.0889ml; 1.5 equivalents) in anhydrous DMF (4ml) and the mixture is stirred at 25°C for 19h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.0N sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (30X2.5cm) using 2% increasing to 3% (10% concentrated ammonium hydroxide in methanol)-dichlor omethane as the eluant to give the title compound (0.2128g; 75% yield), FABMS: m/z 524.9 (MH+). FPT Inhibition = 21% @ 1.1 μM δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.2, 132.2, 126.1 , 130.6, 79.4
C: 119.9, 140.7, 134.0, 136.1 , 136.7, 156.5
Piperidine CH2: 29.2, 51.4, 51.6, 29.2
CH: 43.3
C: 175.3
Piperidine CH2: 42.1
N-substituent CH: 122.3, 149.9, 149.9, 122.3
C: 147.7
EXAMPLE 4. 1 -(3-Br omo-8-chloro-6,11 -dihydr o-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(3-pyridinylmethyl)-4- piperidinecarboxamide
Figure imgf000024_0001
1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yI)-4-piperidinecarboxylate (0.25g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (9ml) is added to a solution of 3-aminomethylpyridine (0.0823ml; 1.5 equivalents), DEC (0.155g; 1.5 equivalents), HOBT (0.1093g; 1.5 equivalents) and N- methylmoφholine (0.0889ml; 1.5 equivalents) in anhydrous DMF (4ml) and the mixture is stirred at 25°C for 18h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 2% (10% concentrated ammonium hydroxide in methanol)-dichlor omethane as the eluant to give the title compound (0.246g; 87%), FABMS: m/z 525 (MH+). FPT IC50 = 1.3 μM δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.3, 132.3, 126.1 , 130.6, 79.4
C: 119.9, 140.7, 134.0, 136.2, 136.7, 156.6
Piperidine CH2: 29.2, 51.4, 51.7, 29.2
CH: 43.4
C: 175.2
Piperidine CH2: 40.9 N-substituent CH: 149.1 , 135.7, 123.7, 148.8
C: 134.2
EXAMPLE 5. 1-(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(2-pyridinylmethyl)-4- piperidinecarboxamide
Figure imgf000025_0001
1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-1 1-yl)-4- piperidinecarboxylate (0.25g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (9ml) is added to a solution of 2- aminomethylpyridine (0.0834ml; 1.5 equivalents), DEC (0.155g; 1.5 equivalents), HOBT (0.1093g; 1.5 equivalents) and N-methylmorpholine (0.0889ml; 1.5 equivalents) in anhydrous DMF (4ml) and the mixture is stirred at 25°C for 18h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 0.85% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.2475g; 87% yield), FABMS: m/z 525 (MH+). FPT IC50 = 1.8 μM δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.2, 132.3, 126.1 , 130.6, 79.5
C: 119.8, 140.7, 133.9, 136.3, 136.7, 156.7
Piperidine CH2: 29.1 , 51.5, 51.7, 29.1
CH: 43.4
C: 175.1
Piperidine CH2: 44.2 N-substituent CH: 122.4, 137.1 , 122.2, 148.9
C: 156.2
EXAMPLE 6. 1-(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(2-pyridinylethyl)-4- piperidinecarboxamide
Figure imgf000026_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-4-piperidinecarboxylate (0.4g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (14ml) is added to a solution of 2-aminoethylpyridine (0.134ml; 1.3 equivalents), DEC (0.215g; 1.3 equivalents), HOBT (0.1515g; 1.3 equivalents) and N-methylmorpholine (0.123ml; 2.6 equivalents) in anhydrous DMF (6ml) and the mixture is stirred at 25°C for 67h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 1% increasing to 2% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.4003g; 86% yield), FABMS: m/z 539.2 (MH+). FPT Inhibition = 9% @ 1.1 μM δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.2, 132.3, 126.1 , 130.6, 79.5
C: 119.8, 140.7, 133.9, 136.4, 136.7, 156.8
Piperidine CH2: 29.1 , 29.1 , 51.5, 51.7
CH: 43.5
C: 174.9
Piperidine CH2: 38.6, 36.7
N-substituent CH: 123.6, 136.9, 121.7, 149.0
C: 159.7
EXAMPLE 7. 1-(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[4-(N-carboxamidopiper idinyl)]-4- piperidinecarboxamide
Figure imgf000027_0001
Step A:
1 -(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-1 yl)-N-[4-(N-benzylpiperidinyl)]-4-piperidinecarboxamide
Figure imgf000028_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-4-piper idinecar boxylate (0.8g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (29ml) is added to a solution of 1 -N-benzyl-4-aminopiperidine (0.4573ml) (1.3 equivalents), DEC (0.43g; 1.3 equivalents), HOBT (0.303g; 1.3 equivalents) and N- methylmorpholine (0.494ml; 2.6 equivalents) in anhydrous DMF (12.8ml) and the mixture is stirred at 25°C for 18h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 2% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.8143g; 78% yield), FABMS: m/z 607.1 (MH+).
Figure imgf000028_0002
Step B:
1-(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 - yl)-N-(4-piperidinyl)-4-piperidinecarboxamide
Figure imgf000029_0001
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-[4-(N-benzylpiperidinyl)]-4-piperidinecarboxamide (0.51 g; 1 equivalent) (prepared as described in Step A above) is dissolved in anhydrous dichloromethane (3ml) and the solution is cooled to 0°C. α-
Chloroethoxycarbonyl chloride (0.09027ml; 1 equivalent) is added over 5 minutes and the solution is allowed to warm to 25°C over 1 h. The dichloromethane is removed in vacuo and anhydrous methanol (14ml) is added. The solution is heated under reflux for 1h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 2.5% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give unreacted 1-(3- bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta [1 ,2-b]pyridin-1 1 -yl)-N- [4-(N-benzylpiperidinyl)]-4-piperidinecarboxamide (0.1921g; 38%yield) and the title compound (0.199g;46%), FABMS: m/z 517.5 (MH+). FPT Inhibition = 8.75% @ 0.39 μM
δc (CDCI3+CD3OD)
Tricyclic CH2: 30.3, 30.2
CH: 146.6, 141.4, 132.2, 126.1 , 130.5, 79.2
C: 119.8, 140.6, 133.9, 136.1 , 136.9, 156.7
Piperidine CH2: 29.0, 51.4, 51.7, 29.0
CH: 43.4
C: 175.0
Piperidine CH2: 44.9, 44.9, 32.0, 32.0 N-substituent CH: 46.0
Step C: 1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6] cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[4-(N-carboxamidopiperidinyl)]-4- piperidinecarboxamide
Figure imgf000030_0001
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinyl)-4-piperidinecarboxamide (0.1191g; 1 equivalent) (prepared as described in Step B above) is dissolved in anhydrous dichloromethane (3.3ml). Trimethylsilylisocyanate (0.467ml; 15 equivalents) is added and the mixture is stirred under argon at 25°C for 22h. Additional trimethylsilylisocyanate (0.156ml; 5 equivalents) is added and the mixture is stirred for a total of 27h. The solution is diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (15X2.5cm) using 4% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.0678g; 53% yield), FABMS: m/z 560 (MH+). FPT Inhibition = 15% @ 0.36 μM
δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.8, 141.2, 132.2, 126.1 , 130.6, 79.4
C: 119.8, 140.7, 133.9, 136.2, 136.7, 156.7
Piperidine CH2: 29.1 , 51.4, 51.7, 29.1
CH: 43.5
C: 174.7
Piperidine CH2: 43.3, 43.3, 31.9, 31.9
N-substituent CH: 46.3
C: 158.1
EXAMPLE 8. 1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11-yl)-N-[4-(N-carboxamidopiperidinyl)methyl]-4-piperidinecarboxamide
Figure imgf000031_0001
Procedure 1 , Step A:
1 -(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6] cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[4-(N-benzylpiperidinyl)methyl]-4- piperidinecarboxamide
Figure imgf000031_0002
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin- 11 - yl)-4-piper idinecarboxylate (0.8g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (29m!) is added to a solution of 1-N-benzyl-4-aminomethylpiperidine (0.4581 g; 1.3 equivalents) (prepared as described in Preparative Example 4, Step B below), DEC (0.43g) (1.3 equivalents), HOBT (0.303g; 1.3 equivalents) and N- methylmorpholine (0.493ml; 2.6 equivalents) in anhydrous DMF (12.8ml) and the mixture is stirred at 25°C for 24h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 2% (10% concentrated ammonium hydroxide in methanoI)-dichloromethane as the eluant to give the title compound (0.7475g; 70% yield), FABMS: m/z 621.6 (MH+).
δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.2, 132.2, 126.1 , 130.6, 79.5
C: 119.8, 140.7, 133.9, 136.3, 136.7, 156.8
Piperidine CH2: 29.3, 51.5, 51.8, 29.3
CH: 43.7
C: 175.1
Piperidine CH2: 53.3, 29.9, 29.9, 53.3, 63.4, 44.9
N-substituent CH: 36.0, 128.2, 129.2, 127.0, 129.2, 128.2
C: 138.3
Step B:
1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11- yl)-N-(4-piperidinyl)-4-piperidinecarboxamide
Figure imgf000032_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-N-[4-(N-benzylpiperidinylmethyl)]-4-piperidinecarboxamide (0.568g; 1 equivalent) (prepared as described in Step A above) is dissolved in anhydrous dichloromethane (5.9ml) and the solution is cooled to 0°C. α- Chloroethoxycarbonyl chloride (0.487ml; 5 equivalents) is added over 30 minutes and the solution is allowed to warm to 25°C over 2.5h. The dichloromethane is removed in vacuo and anhydrous methanol (14.2ml) is added. The solution is heated under reflux for 1.25h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (30X2.5cm) using 2% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give unreacted 1-(3-bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta [1 ,2-b]pyridin-11-yl)-N-[4-(N-benzylpiperidinyl)]-4- piperidinecarboxamide (0.1487g; 23% yield) and the title compound (0.1932g; 34% yield), FABMS: m/z 531.0 (MH+). The title compound is identical to that prepared in Procedure 2, Step B below. FPT Inhibition = 12% @ 0.38 μM
δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.2, 132.2, 126.1 , 130.6, 79.5,
C: 119.8, 140.7, 133.9, 136.3, 136.7, 156.7
Piperidine CH2: 29.3, 51.5, 51.7, 29.3
CH: 43.7
C: 175.2
Piperidine CH2: 30.9, 30.9, 46.2, 46.2, 45.2 N-substituent CH: 36.5
StepC:
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 ■ yl)-N-[4-(N-carboxamidopiperidinyl)methyl]-4-piperidinecarboxamide
Figure imgf000033_0001
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 ■ yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (0.005g; 1 equivalent) (prepared as described in Step B above) is dissolved in anhydrous dichloromethane (0.161 ml). Trimethylsilylisocyanate (0.0038ml; 3 equivalents) is added and the mixture is stirred at 25°C under argon for 16h. The mixture is diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness to give the title compound which is identical on thin layer chromatography (TLC) to that prepared in Procedure 2, Step C below.
Procedure 2, Step A:
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6] cyclohepta[1 ,2-b]pyridin-11 yl)-N-[4-(N-ferf -butoxycarbonylpiperidine)methyl]-4-piperidinecarboxamide
Figure imgf000034_0001
1-(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-4-piperidinecarboxylate (0.5g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (18ml) is added to a solution of 1-N-fe/t -butoxycarbonyl-4-aminomethylpiperidine (0.1778g; 1 equivalent) (prepared as described in Preparative Example 3, Step C below), DEC (0.2067g; 1.3 equivalents), HOBT (0.1457g; 1.3 equivalents) and N- methylmorpholine (0.1185ml; 1.3 equivalents) in anhydrous DMF (8ml) and the mixture is stirred at 25°C for 19h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.0N sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 0.75% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.4805g; 71% yield), FABMS: m/z 631 (MH+).
δc (CDCI3) Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.2, 132.2, 126.1 , 130.6, 79.5
C: 119.8, 140.7, 133.9, 136.3, 136.7, 156.7
Piperidine CH2: 29.8, 51.7, 51.4, 29.3
CH: 43.6
C: 175.2
Piperidine CH3: 28.5 N-substituent CH2: 43.6, 43.6, 29.3, 29.3, 44.7
CH: 36.4
C: 79.5, 154.8
Step B:
1-(3-Bromo-8-chlor o-6,11-dihydro-5H-benzo[5,6]hepta[1 ,2-b]pyridin-11-yl)-N-
(4-piperidinylmethyl)-4-piperidinecarboxamide
Figure imgf000035_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-[4-(N-ferf -butoxycarbonylpiperidine)methyl]-4-piperidine carboxamide (0.3936g; 1 equivalent) is dissolved in anhydrous dichloromethane (30ml). Trifluoroacetic acid (6.039ml; 127 equivalents) is added to the stirred solution at 0°C under argon. The mixture is stirred at 0°C for 1.5h and then allowed to warm to 25°C for 1 h. The mixture is diluted with dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 7% increasing to 10% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.2023g; 61% yield), FABMS: m/z 531.1 (MH+). δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.9, 141.2, 132.2, 126.1 , 130.6, 79.5
C: 119.8, 140.7, 133.9, 136.3, 136.7, 156.7
Piperidine CH2: 29.3, 51.4, 51.7, 29.3
CH: 43.7
C: 175.1
Piperidine CH2: 30.7, 30.7, 46.1 , 46.1 , 45.2 N-substituent CH: 36.4
Step C.
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6] cycloheptap ,2-b]pyr idin-11 -yl)-N-[4-(N-carboxamidopiperidinyl)methyl]-4- piperidinecarboxamide
Figure imgf000036_0001
1 -(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (0.140g; 1 equivalent) (prepared as described in Step B above) is dissolved in anhydrous dichloromethane (4.5ml). Trimethylsilylisocyanate (0.534ml) (15 equivalents) is added and the mixture is stirred at 25°C under argon for 18h. The mixture is diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (30X2.5cm) using 4% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.1084g; 72% yield), FABMS: m/z 573.9 (MH+). FPT Inhibition = 41% @ 1.04 μM δc (CDCI3)
Tricyclic CH2: 30.4, 30.3
CH: 146.8, 141.2, 132.2, 126.1 , 130.6, 79.5
C: 119.8, 140.7, 133.9, 136.3, 136.7, 156.7
Piperidine CH2: 29.3, 51.4, 51.7, 29.3
CH: 43.5
C: 175.4
Piperidine CH2: 29.6, 29.6, 44.6, 44.6, 44.1
N-substituent CH: 36.1
C: 158.1
EXAMPLE 9. 1 -[1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-4-piperidinylcarbonyl]-4-[(1 ■ aminomethanamido)methyl]piperidine
Figure imgf000037_0001
Step A:
1-[1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin- 11 -yl)-4-piperidinylcarbonyl]-4-[(N-terf -butoxycarbonylamino)methyl]piperidine
NHBOC
Figure imgf000038_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-4-piperidinecarboxylate (0.3195g; 1 equivalent) (prepared as described in Preparative Example 2 below) dissolved in anhydrous DMF (11.5ml) is added to a solution of 4-[(N-tert -butoxycarbonylamino)-methyl]piperidine (0.1904g; 1.3 equivalents) (prepared as described in Preparative Example 5, Step C below), DEC (0.1703g; 1.3 equivalents), HOBT (0.1201g; 1.3 equivalents) and N-methylmorpholine (0.195ml; 2.6 equivalents) in anhydrous DMF and the mixture is stirred at 25°C for 19h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 0.8% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.3701 g; 86% yield), FABMS: m/z 631.3 (MH+).
δc (CDCI3)
Tricyclic CH2: 30.7, 30.4
CH: 146.8, 141.2, 132.2, 126.0, 130.6, 79.6
C: 119.7, 140.7, 133.8, 136.4, 136.7, 156.9
Piperidine CH2: 51.6, 29.1 , 28.9, 51.9
CH: 38.8
C: 173.4
Piperidine CH3: 28.4
N-substituent CH2: 45.3/45.9, 28.9/29.1 , 29.5/30.2, 45.3/45.9, 41.7
CH: 37.0
C: 79.4, 156.1
Step B: 1 -[1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin- 11 -yl)-4-[piperidinyl]-4-aminomethylpiperidine
Figure imgf000039_0001
1-[1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta [1 ,2-b] pyridin- 11 -yl)-4-piperidinylcarbonyl]-4-[(N-fert -butoxycarbonylamino) methyl]piperidine (0.35g) (1 equivalent) is dissolved in methanol (3.1ml). A 10% (v/v) solution of concentrated sulfuric acid in dioxane (7.568ml) is added and the mixture is stirred at 25°C under argon for 1.5h. The mixture is stirred at 0°C for 1.5h and then allowed to warm to 25°C for 1 h. The mixture is diluted with dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (30X2.5cm) using 4% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.226g; 77% yield), FABMS: m/z 531.4 (MH+). FPT Inhibition = 16% @ 0.38 μM δc (CDCI3)
Tricyclic CH2: 30.4, 30.2
CH: 146.8, 141.2, 132.2, 126.0, 130.6, 79.6
C: 119.8, 140.7, 133. 8, 136.4, 136.7, 156.9
Piperidine CH2: 51.6, 29.1 , 28.9, 51.9
CH: 38.8
C: 173.3
Piperidine CH2: 42.0, 29.7/30.9, 29.0/29.2, 42.0, 45.5 N-substituent CH: 38.8
Step C:
I -[1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-
I I -yl)-4-piperidinylcarbonyl]-4-[(1 -aminomethanamido)methyl]piperidine
Figure imgf000040_0001
1-[1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b] pyridin- 11-yl)-4-piperidinylcarbonyl]-4-[(N-ferf -butoxycarbonylamino) methyl]piperidine (0.185g) (1 equivalent) (prepared as described in Example 9, Step B above) is dissolved in anhydrous dichloromethane (5ml). Trimethylsilylisocyanate (0.706ml) (15 equivalents) is added and the mixture is stirred at 25°C under argon for 22h. Additional trimethylsilylisocyanate (0.235ml) (5 equivalents) is added and the stirring is continued for a total of 26.75h. The mixture is diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (30X2.5cm) using 3.5% (10% concentrated ammonium hydroxide in methanol)-dichloromethane to give the title compound (0.1502g; 75% yield), FABMS: m/z 574.2 (MH+).
Figure imgf000040_0002
EXAMPLE 10. 1 -(8-chloro-3-bromo-5,6-dihydro-11 H-benzo[5,6]- cyclohepta[1 ,2-b]pyridin-11-yl)piperidine-3-(N-3- pyridylmethylamino)carboxamide
Figure imgf000041_0001
Procedure 1 , Step A.
Ethyl 1 -(3-bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11-yl)-3-piperidinecarboxylate
Figure imgf000041_0002
3-Bromo-8,1 1 -dichloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine (1g, 2.5 mmol) is dissolved in 10 mL of N,N-dimethylformamide (DMF). Ethylnipecotate (0.6 ml, 3.7 mmol) and N-methylmorpholine (0.69 mL, 6.2 mmol) are added and the reaction mixture is stirred at ambient temperature for 18 hours. The reaction mixture is poured into water and extracted with dichloromethane two times. The combined extracts are dried over magnesium sulfate and the mixture filtered and evaporated to obtain an oil. The oil is chromatographed on silica gel using 10% ethyl acetate/hexanes as the eluent to obtain 0.55 gm of the title compound. FABMS (MH+)=464
Step B. 1-(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 - yl)-3-piperidinecarboxylate
Figure imgf000042_0001
Ethyl 1 -(3-bromo-8-chlor 0-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11-yl)-3-piperidinecarboxylate (1.9 gm) is refluxed in 25 ml of 6N hydrochloric acid for 8 hours. The HCI and water is evaporated to obtain the title compound, as a solid.
Step C.
1 -(3-Bromo-8-chloro-6,1 1-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11- yl)-N-(3-pyridinylmethyl)-3-piperidinecarboxamide
Figure imgf000042_0002
The compound from Example 10, Step B is dissolved in 12 mL of DMF and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC) (0.37 g 1.9 mmol), 1 -hydroxybenzotriazole (HOBT) (0.36g), NMM (0.5 mL) and (0.216 g, 2.0 mmol) of 3-aminomethylpyridine are added and the reaction mixture is stirred at ambient temperature. After 17 hours the reaction mixture is poured into water and extracted with dichloromethane two times. The combined extracts are dried over magnesium sulfate and the mixture filtered and evaporated to obtain an oil. The oil is chromatographed on silica gel using 5% methanol/dichloromethane as the eluent to obtain 0.44 gm of the title compound. FABMS (MH+)=603 FPT IC50 = 0.21 μM
Step D. Separation of Isomers The compound of Example 10, Procedure 1 , Step C, is separated into its four optical isomers by HPLC chromatography with a Chiralpak® AD analytical (0.46cmX25cm) chiral column (amylose tris(3,5-dimethylphenyl carbamate) coated on a 10 μM silica-gel substrate (trademark of of Chiral Technologies, Exton, Pennsylvania), using as the eluting solvent, 20% isopropanlol/ hexanes/.02% diethylamine at 1mL. minute, the four compounds elute at 10.27 (Isomer A), 11.43 (Isomer B), 11.57 (Isomer C) and 18.37 (Isomer D) minutes.
Figure imgf000043_0001
FABMS(MH+)=526.8 FABMS(MH+)=526.8
FPT Inhibition = 6.1%@ 1.14μM FPT IC50 = 0.194μM
Figure imgf000043_0002
FABMS(MH+)=526.8 FABMS(MH+)=526.8 FPT IC5o = 0.179μM FPT IC50 = 0.187μM
Procedure 2. Step A.
Figure imgf000044_0001
To a solution of N-(tert-butoxycarbonyl)nipecotic acid (0.50 g, 2.41 mmol) in dichloromethane (10 mL) is added 3-(aminomethyl)pyridine (0.27 mL, 2.65 mmol), 1 -hydroxybenzotriazole monohydrate (HOBT) and 1 ,3- dicyclohexylcarbodiimide (0.547 g, 2.65 mmol). The mixture is stirred at room temperature for 16 hr and is then filtered. The solution is purified by flash chromatography (Si02. 2% methanol in CH2CI2) affording 0.67g of the product.
Step B.
Figure imgf000044_0002
A solution of the product of Example 10, Procedure 2, Step A, (0.04g, 0.125 mmol) in CH2CI2 (3 mL) is treated with trifluoroacetic acid (TFA) (0.5 mL) for 1 hr. The mixture is then evaporated to dryness in vacuo and azeotroped with methanol (3 x 5mL portions).
Step C.
Figure imgf000044_0003
The residue from Example 10, Procedure 2, Step B above, is then dissolved in CH3CN (1 mL) and a solution of 3-bromo-8,11-dichloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine (0.07 g, 0.2 mmol) in CH3CN is added, followed by 1 ,2,2,6, 6-pentamethylpiperidine (0.2 mL, 1.1 mmol). The solution is heated at 45°C for 16 hr and then evaporated to dryness in vacuo. The residue is purified by flash chromatography (Siθ2, 3% methanol in CH2CI2) affording 0.04g of the title compound.
1 H NMR (300 Mhz) CDCI3; d=1.45-1.75 (m, 2H); 1.8-1.92 (m, 1 H); 2.02-2.15 (m, 1 H); 2.16-2.30 (m, 1 H); 2.38-2.52 (m, 2H); 2.58-2.72 (m, 2H); 3.16-3.3 (m, 1 H); 3.46-3.70 (m, 2H); 3.70-3.82 (m, 1 H); 4.32 (br. s, 2H); 4.39 (d, 1 H); 4.45- 4.52 (m, 1 H); 6.93 (br. s, 0.5 H); 7.06-7.17 (m, 3H); 7.22-7.28 (m, 1 H); 7.35 (br. s, 0.5H); 7.45-7.52 (m, 1 H); 7.53 (d, 0.5H); 8.38 (d, 0.5H); 8.49 (br. s, 1 H); 1.58 (m, 1 H).
EXAMPLE 11. 1 -(3-bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta [1 ,2-b]pyridin-1 1 -yl)-N-(3-pyridinyl)-3-piperidinecarboxamide
Figure imgf000045_0001
0 1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 - yl)-3-piperidinecarboxylate (0.12 gm, 0.27 mmol) from Example 10, Procedure 1 , Step B, is dissolved in 4 ml of DMF. 1-(3-Dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (DEC), (79 mg, 0.41 mmol), 1- hydroxybenzotriazole (HOBT) (55 mg, 0.41 mmol), N-methyl morpholine (NMM) (0.29 ml, 2.7 mmol), and 3-amino pyridine (0.05 gm) are added and the reaction mixture is stirred for 18 hours. The reaction mixture is poured into water and extracted with ethyl acetate three times. The combined extracts are dried over magnesium sulfate, filtered and chromatographed on silica gel to obtain 42 mg of title compound. FABMS (MH+)=512.8 FPT IC50 = 0.065 μM
EXAMPLE 12. 1-(3-Bromo-8-chloro-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(4-pyridinylmethyl)-2S- piperidinecarboxamide- Isomer A1 amide
Figure imgf000046_0001
Step A1. L-Pipecolinic Acid Ethyl Ester Hydrochloride.
Figure imgf000046_0002
L-Pipecolinic acid (0.9g, 6.97 mmol) is dissolved in 40 mL of absolute EtOH. HCI gas is bubbled for ~1 minute. The reaction mixture is refluxed for 20 min, cooled and the solvents removed by rotary evaporation to give 1.34g of the title compound, a wax that is used without further purification.
Step A2. D-Pipecolinic Acid Ethyl Ester Hydrochloride.
Figure imgf000046_0003
Using essentially the same conditions as described in Example 12, Step A1 , but replacing L-Pipecolinic acid with D-Pipecolinic acid, the title compound is obtained.
Step B.
Figure imgf000047_0001
Isomer B 1 ester 3-Bromo-8,11-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine (1.10 g, 3.00 mmol) and L-pipecolinic acid ethyl ester hydrochloride from Example 12, Step A1 (1.34 g, 6.98 mmol), triethylamine (2.91 μL, 21 mmol) are dissolved in dry CH2CI2 (20ml) and the mixture is stirred at 25°C under nitrogen for 72h. The reaction mixture is washed with saturated NaHCθ3, H20, brine and then filtered through Na2SU4 and evaporated to dryness. The product is chromatographed on a silica gel column using 1 % ethyl acetate- dichloromethane as the eluant to separate the two separable diastereomeric isomers (i.e. Isomers A1 ester and B1 ester), the less polar being referred to as Isomer A1 ester and the more polar isomer being referred to as Isomer B1 ester. FABMS MH+ = 464.
Figure imgf000047_0002
Isomer A 1 ester Isomer A 1 acid Isomer A1 ester from Example 12, Step B (0.26g, 0.6 mmol) is dissolved in 6 mL of ethanol and 1.4 mL of 1 M LiOH (1.4 mmol) is added. The reaction mixture is heated on oil bath at 80°C for 10h, cooled and 1.5 mL of 1 N HCI is then added to adjust the pH to - 4.5. Solvents are then removed by evaporation and the resulting crude acid is used in the next reaction without further purification.
Step D.
Figure imgf000048_0001
Isomer A 1 acid Isomer A 1 amide Isomer A1 acid from Example 12, Step C ( from 0.26g, 0.6 mmol of Isomer A ester) is dissolved in 3 mL of DMF and NMM (184 μL, 1.6 mmol), 4- (aminomethyl)pyridine (74 μL, 0.078g, 0.73 mmol), HOBT(0.098 g, 0.72 mmol), DEC(0.139g, 0.72 mmol) are then added. The reaction mixture is stirred at room temperature for 16h. DMF is removed by rotary evaporation and the resulting crude mixture is partitioned between EtOAc-NaHCθ3. The organic phase is washed with H2O, brine and filtered though Na2Sθ4 to give crude product that is purified by flash chromatography eluting with 3% (10% NH4θH-CH3θH)-CH2Cl2 solvent system to obtain the title compound, a white solid FAB-MS MH+ = 527 FPT Inhibition = 18% @ 1.1 μM
Example 13. 1 -(3-Bromo-8-chloro-6, 11 -dihydr o-5H-benzo[5,6]cyciohepta[1 ,2- b]pyridin-11-yl)-N-(4-pyridinylmethyl)-2S-piperidinecarboxamide - Isomer B1 amide
Figure imgf000048_0002
Isomer B 1 amide Using the method of Example 12, Steps C and D, except that Isomer B1 ester from Example 12, Step B, is used instead of Isomer A1 ester, the title compound is obtained. MH+ =527 FPT Inhibition = 21 % @ 1.1 μM
Example 14. Using the method of Examples 12 and 13, except that D- pipecolinic acid ethyl ester hydrochloride is used in place of L-pipecolinic acid ethyl ester hydrochloride, the following two diasteriomers are obtained:
Figure imgf000049_0001
Isomer A2 amide Isomer B2 amide
MH+ = 527 MH+ = 527
FPT Inhibition = 0% @ 1.1 μM FPT Inhibition = 13% @ 1.1 μM
Example 15. Using the method of Examples 12-14, except that in Example 12, Step D, 3-(aminomethyl)pyridine is used in place of 4-(aminomethyl)pyridine, the following four diasteriomers are prepared.
Figure imgf000049_0002
Isomer Cl amide Isomer D 1 amide
MH+ = 527 MH+ = 527 melting point (m.p.) = 198.5-199°C m.p. = 180.9-181.5°C
FPT IC50 = 0.3 μM FPT IC50 = 0.16 μM
Figure imgf000050_0001
Isomer C2 amide Isomer D2 amide
MH+ = 527 MH+ = 527 m.p. = 168.2-168.4°C m.p. = 205.5-206.4°C
FPT Inhibition = 11% @ 0.38 μM FPT Inhibition = 0% @ 0.38 μM
Example 16. 1-(3,10-Dibromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(3-pyridinylmethyl)-3- piperidinecarboxamide
Figure imgf000050_0002
Using the method of Example 10, Procedure 1 , except that the compound 3,10-dibromo-8, 11 -dichloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridine is substituted for 3-bromo-8, 11 -dichloro-6, 1 1 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine, the title compound is obtained. FABMS MH+=605.7 FPT IC50 = 0.027μM
EXAMPLE 17 1 -(3,10-Dibromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(3-pyridinylmethyl)-3- piperidinecarboxamide
Using the method of Example 10, Procedure 1 , except that the compound 3, 10-dibromo-8, 11 -dichloro-6, 11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridine is substituted for 3-bromo-8, 11 -dichloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine and optically pure ethylnipecotate is used, the title compound is obtained. Optically pure ethylnipecotate can be prepared from L-tartaric acid according to (Reel. Trav. Chim. P. 899, 1951 ).
Separation of the resulting two isomers by HPLC chromatography is performed on a Chiral Technlogies AD analytical (0.46cmX25cm) chiral column using 10% isopropanol/hexanes/0.02% diethylamine at 1 mL. minute. The two compounds are eluted at 14.85 (Isomer A) and 24.7 (Isomer B) minutes.
Figure imgf000051_0001
Isomer A Isomer B
MH+ = 605.7 MH+ = 605.7
FPT IC50 < 0.0099 μM FPT Inhibition = 3.4% at 0.1 μM
EXAMPLE 18. 1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(3-pyridinylmethyl)-3- piperidineacetamide
Figure imgf000051_0002
Using the method of Example 10, Procedure 1 , except that 3-ethylpiperidineacetate is substituted for ethylnipecotate, the title compound is obtained. FABMS(MH+) = 541.0 FPT Inhibition = 9% @ 1.1 μM EXAMPLE 19. 1-(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(3-pyridinyl)-3- piperidineacetamide
Figure imgf000052_0001
Using the method of Example 10, Procedure 1 , except that 3-ethylpiperidineacetate is substituted for ethylnipecotate, and Example 11 , except that nicotinic acid is substituted for 3-pyridylacetic acid, the title compound is obtained. FABMS(MH+)= 526.9 FPT Inhibition = 15% @ 1.1 μM
EXAMPLE 20.
Figure imgf000052_0002
1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-4-piperidinecarboxylate (1 equivalent) (prepared as described in Preparative Example 2 ) is reacted with 1-N-methyl-4-(aminomethyl)- piperidine (1.3 equivalents) (prepared by reductive formylation of 4- ethoxycar bonylaminomethylpyridine, followed by hydrolysis of the protecting group under standard conditions) under similar conditions to those described in Preparative Example 2, below, to give the title compound.
EXAMPLE 21
Figure imgf000053_0001
1-(3-Bromo-8-chloro-6,1 1-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) is reacted with 2-bromoacetamide (1.1 equivalents) and sodium carbonate in anhydrous DMF at 25°C to give the title compound.
Figure imgf000053_0002
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) is reacted with an excess of acetic anhydride in methanol at 25°C for 24h to give the title compound.
EXAMPLE 23
Figure imgf000054_0001
1 -(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) is reacted with chloroacetyl chloride (1.1 equivalents) and triethylamine (2 equivalents) in dichloromethane to give the intermediate chloroacetate. The latter is reacted with an excess of dimethylamine in the presence of sodium carbonate in DMF at 25°C to give the title compound.
EXAMPLE 24
Figure imgf000055_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) is reacted with ethylchloroformate (1.1 equivalents) in anhydrous dichloromethane at 25°C for 24h to give the title compound.
EXAMPLE 25
NHBOC
Figure imgf000056_0001
1 -(3-Bromo-8-chlor o-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) is reacted with N-(tert -butoxycarbonyl)glycine (1.3 equivalents), DEC. HCI (1.3 equivalents), HOBT (1.3 equivalents) and N-methylmorpholine (1.3 equivalents) in anhydrous DMF at 25°C for 24h to give the N-BOC intermediate. The latter is dissolved in methanol and reacted with 10% concentrated sulfuric acid in dioxane at 25°C for 2h to give after basification and chromatography on silica gel, the title compound.
EXAMPLE 26
Figure imgf000057_0001
1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in dichloromethane is reacted with phenyl cyanate (2 equivalents) and diisopropylethylamine at 25°C for 15 minutes to give the title compound.
Figure imgf000057_0002
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) and diphenylcyanocarbonimidate (1.2 equivalents) are dissolved in 2-propanol and the mixture is heated at 80°C for 24h to give the title compound.
Figure imgf000058_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) and diphenylsulfamoylcarbonimidate (1.2 equivalents) [prepared as described in: M. Haake and B. Schummelfeder, Synthesis, 753-758 (1991 )] are dissolved in 2-propanol and the mixture is heated at 80°C for 24h to give the title compound.
Figure imgf000058_0002
The phenoxyimidate (1 equivalent) (prepared as described in Example 26 above) is dissolved in anhydrous THF. A 60% sodium hydride dispersion in oil 4 equivalents) is added and the mixture is stirred at 25°C for 2h. The mixture is diluted with dichloromethane and washed with 1 N sodium hydroxide. Chromatography on silica gel affords the title compound.
Figure imgf000059_0001
The phenoxyimidate (1 equivalent) (prepared as described in Example 26 above) is dissolved in concentrated ammonium hydroxide and ammonium chloride (1 equivalent) is added. The mixture is heated in a sealed tube at 90°C to give the title compound.
EXAMPLE 31
Figure imgf000060_0001
The N-cyanophenoxyimidate (1 equivalent) (prepared as described in Example 27 above) is dissolved in concentrated ammonium hydroxide and the mixture is stirred at 25°C for 24h to give the title compound.
EXAMPLE 32
Figure imgf000060_0002
The N-sulfamoylphenoxyimidate (1 equivalent) (prepared as described in Example 28 above) is dissolved in concentrated ammonium hydroxide and the mixture is stirred at 25°C for 24h to give the title compound.
EXAMPLE 33
Figure imgf000061_0001
The phenoxyimidate (1 equivalent) (prepared as described in Example 26 above) is dissolved in methanol. An aqueous solution of methoxylamine (1 equivalent) [prepared by dissolving methoxylamine hydrochloride (1 equivalent) in 50% (w/v) sodium hydroxide (1 equivalent)] is added and the mixture is stirred at 25°C to give the title compound.
EXAMPLE 34
Using the method of Example 14 except that 3, 10-dibromo-8, 11 -dichloro-6, 11 dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine is substituted for 3-bromo- 8,11 -dichloro-6, 11-dihydro-5H benzo[5,6]cyclohepta[1 ,2-b]pyridine, the following two compounds are obtained:
Figure imgf000061_0002
Isomer C3 amide Isomer D3 amide MH+ = 605 MH+ = 605 FPT IC50 = 0.3 μM FPT IC50 = 0.0.0042 μM
EXAMPLE 35
Figure imgf000062_0001
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) and sulfamide (10 equivalents) are added to water and the mixture is stirred under reflux at 100°C for 43h to give the title compound.
EXAMPLE 36
Figure imgf000062_0002
1-(3-Bromo-8-chloro-6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in dichloromethane is reacted with dimethylsulfamoyl chloride (1.1 equivalents) in the presence of triethylamine (2 equivalents) at from 0°C to 25°C to give the title compound.
EXAMPLE 37
Figure imgf000063_0001
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in dichloromethane is reacted with methanesulfonyl chloride (1.1 equivalents) in the presence of triethylamine (2 equivalents) at 25°C to give the title compound.
EXAMPLE 38
Figure imgf000063_0002
1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in DMF is reacted with dimethylphosphinic chloride (1.1 equivalents) and sodium carbonate at 25°C to give the title compound.
EXAMPLE 39
Figure imgf000064_0001
Figure imgf000064_0002
1 -(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11- yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in DMF is reacted with tetra-O-acetyl-D-glucopyranosyl bromide (1.1 equivalents) in the presence of sodium carbonate to give the title compound.
EXAMPLE 40
Figure imgf000065_0001
1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 - yl)-N-(4-piperidinylmethyl)-4-piperidinecarboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in DMF is reacted with 2-chloropyridine (1.1 equivalents) in the presence of sodium carbonate to give the title compound.
EXAMPLE 41
Figure imgf000065_0002
Benzanilide is converted into the choloroimidate (as described in: A. C. Honz and E. C. Wagner, Org. Syn. Coll. Vol. 4, 383-386 (1963) (1.1 equivalents) and this is reacted with 1 -(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 -yl)-N-(4-piper idinylmethyl)-4- piperidine-carboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above) in pyridine at reflux temperature to give the title compound.
Figure imgf000066_0001
Copper(l)chloride (1 equivalent) is dissolved in anhydrous acetonitrile. To this solution, a solution of 1-(3-Bromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 -yl)-N-(4-piperidinylmethyl)-4- piperidine-carboxamide (1 equivalent) (prepared as described in Example 8, Procedures 1 or 2, Step B above), 1-methylthio-1-methylamino-2-nitroethene (1 equivalent) (prepared as described in Canadian Patent 1 ,178,289 (1984)) and triethylamine in anhydrous acetonitrile is added dropwise over 10 minutes with stirring. The solid is filtered off The volume is reduced and dichloromethane is added. The mixture is washed with aqueous sodium bicarbonate and the dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The residue is purified on silica gel to give the title compound.
Example 43. 1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11-yl)-N-(3-pyridylmethyl)-4-piperidineacetamide
Figure imgf000066_0002
3-Bromo-8,11 -dichloro-6, 11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine (0.317g, 0.924mmoles) is dissolved in anhydrous THF (4.6ml). N-(3- pyridylmethyl)-4-piperidineacetamide (prepared as described in Preparative Example 7, Step B) (0.2803g, 1.2mmoles) and triethylamine (0.386ml, 2.77mmoles) in anhydrous dichloromethane (5ml) are added and the mixture is stirred at 25°C for 18h. The solution is diluted with dichloromethane and washed with 1 N NaOH , dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on silica gel using 4% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.219g, 44%), SIMS: m/z 539 (MH+), FPT INH 43% @ 0.22μM.
dc (CDCI3)
Tricyclic: CH2: 30.3, 30.5
CH: 79.5, 126.1 , 130.5, 132.4, 141.1 , 146.9
C: 120.2, 126.4, 134.1 , 135.5, 136.4, 143.5,
154.0
Piperidine: CH2: 41.0, 46.8, 47.0, 50.9, 50.9
CH: 33.5
C: 172.0
Pyridine CH2: 43.6 substituent: CH: 123.7, 135.7, 148.9, 149.1
C: 133.8
Example 44. 1 -(3-Bromo-8-chloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyr idin-11 -yl)-N-(3-pyridylmethyl)-4-piperidinepropanamide
Figure imgf000067_0001
3-Bromo-8,11 -dichloro-6, 11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyr idine (0.317g, 0.924mmoles) is dissolved in anhydrous THF (5ml). N-(3- pyridylmethyl)-4-piperidinepropanamide (prepared as described in Preparative Example 8, Step C) (0.2972g, 1.2mmoles) and triethylamine (0.386ml, 2.77mmoles) in anhydrous dichloromethane (20ml) are added and the mixture is stirred at 25°C for 20h. The solution is diluted with dichloromethane and washed with 1 N NaOH , dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on silica gel using 2.5% (10% cone, ammonium hydroxide in methanol)- dichloromethane as the eluant to give the title compound (0.3022g, 59%), ESIMS: m/z 553.2 (MH+), FPT INH 39% @ 0.35μM.
Example 45. 1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-(3-pyridylmethyl)-4- piperidineacetamide
Figure imgf000068_0002
3,10-Dibromo-8,11-dichloro-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2- b]pyridine (prepared as described in Preparative Example 6, Step F) (0.2426g, 0.575mmoles) is dissolved in anhydrous THF (2.86ml). N-(3- pyridylmethyl)-4-piperidineacetamide (prepared as described in Preparative Example 7, Step B) (0.175g, 0.748mmoles) and triethylamine (0.24ml, 1.725mmoles) in anhydrous THF (5ml) are added and the mixture is stirred at 25°C for 138h. The solution is evaporated to dryness and the residue is dissolved in dichloromethane and washed with 1 N NaOH , dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on silica gel using 5% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.021 g, 6%), ESIMS: m/z 617.2 (MH+), FPT IC50 =0.042μM.
δc (CDCI3)
Tricyclic: CH2: 32.4, 32.4
CH: 75.6, 129.6, 130.7, 141.6, 147.2
C: 119.9, 126.2, 133.8, 136.2, 136.2, 143.2, 155.0
Piperidine: CH2: 29.9, 31.2, 41.0, 51.0, 51.5
CH: 33.4
C: 171.9
Pyridine CH2: 43.6 substituent: CH: 123.7, 135.7, 148.9, 149.1
C: 134.1
Example 46. 4-Carboxamido-1-[1-(8-chloro-3,10-dibromo-6,1 1-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-4-piperidineacetyl]piperidine
Figure imgf000069_0001
1 -(8-Chlor 0-3, 10-dibromo-6, 11 -dihydro-5H-benzo[5,6] cyclohepta [1 ,2- b]pyridin-11-yl)-4-piperidineacetic acid (0.5287g, Immole) (prepared as described in Preparative Example 10, Step B), isonipecotamide (0.1666g, 1.3mmoles), DEC.HCI (0.2492g, 1.3mmoles), HOBT (0.1757g, 1.3mmoles) and NMM (0.1315g, 1.3mmoles) are dissolved in anhydrous DMF (10ml) and the mixture is stirred at 25°C under argon for 24h. The solution is evaporated to dryness and the residue is dissolved in dichloromethane, washed with 1 N NaOH, dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on silica gel using 0.75% (10% cone, ammonium hydroxide in methanol)-dichlor omethane as the eluant to give the title compound.
Example 47. 3- Carboxamido-1 -[1 -(8-chloro-3, 10-dibromo-6, 11 -dihydr o-5H- benzo[5,6]cyclohepta[1 ,2-b]pyr idin-11 -yl)-4-piperidineacetyl]piperidine
Figure imgf000070_0001
1 -(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta [1 ,2- b]pyridin-11 -yl)-4-piperidineacetic acid (0.5287g, I mmole) (prepared as described in Preparative Example 10, Step B) and nipecotamide (0.1666g, 1.3mmoles), DEC.HCl (0.2492g, 1.3mmoles), HOBT (0.1757g, 1.3mmoles) and NMM (0.1315g, 1.3mmoles) are dissolved in anhydrous DMF (10ml) and the mixture is stirred at 25°C under argon for 24h. The solution is evaporated to dryness and the residue is dissolved in dichloromethane, washed with 1 N NaOH, dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on silica gel using 0.75% (10% cone, ammonium hydroxide in methanol)-dichlor omethane as the eluant to give the title compound.
Example 48. 4-[1 -(8-Chloro-3, 10-dibromo-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-4-piperidineacetyl]-1 ■ piperazinecarboxamide
Figure imgf000070_0002
Step A. 4-[1-(8-Chloro-3,10-dibromo-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-4-piperidineacetyl]-1 -N-tert -butoxycarbonylpiperazine
Figure imgf000071_0001
1 -(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta [1 ,2- b]pyridin-11-yl)-4-piperidineacetic acid (0.5287g, I mmole) (prepared as described in Preparative Example 10, Step B) and 1-N-fert- butoxycarbonylpiperazine (0.1667g, 1.3mmoles), DEC.HCI (0.2492g, 1.3mmoles), HOBT (0.1757g, 1.3mmoles) and NMM (0.1315g, 1.3mmoles) are dissolved in anhydrous DMF (10ml) and the mixture is stirred at 25°C under argon for 24h. The solution is evaporated to dryness and the residue is dissolved in dichloromethane, washed with 1 N NaOH, dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on silica gel using 0.75% (10% cone, ammonium hydroxide in methanol)- dichloromethane as the eluant to give the title compound.
Step B. 1-[1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b] pyridin-11 -yl)-4-piperidineacetyl]piperazine
Figure imgf000071_0002
4-[1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1 ,2- b]pyridin-1 1 -yl)-4-piperidineacetyl]-1 -N-tert -butoxycarbonylpiperazine (prepared as described in Step A above) is converted into 1-[1-(8-Chloro- 3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11-yl)-4- piperidineacetyl]piperazine by essentially the same procedure as described in Example 8, Procedure 2, Step B.
Step C. 4-[1 -(8-Chloro-3, 10-dibromo-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11 -yl)-4-piperidineacetyl]-1 -piperazinecarboxamide
Figure imgf000072_0001
1-[1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11-yl)-4-piperidineacetyl]piperazine (prepared as described in Step B above) is converted into 4-[1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-4-piperidineacetyl]-1 - piperazinecarboxamide by essentially the same procedure as decribed in Example 8, Procedure 2, Step C above.
Example 49. N-cyclopropyl-1-(3,10-dibromo-8-chloro-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-3-piperidinecarboxamide
Figure imgf000072_0002
Following the method of Example 10, Procedure 1 , except that (a) the compound 3,10-dibromo-8, 10-dichloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine is substituted for 3-bromo-8,10-dichloro- 6,1 -dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine in Step A, and (b) cyclopropyl amine is substituted for 3-aminomethylpyridine in Step C, the title compound is obtained. FABMS (MH+ ) = 554. FPT IC50 = 0.58 uM.
Example 50. 1 -(3, 10-Dibromo-8-chloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-methyl-3-piperidinecarboxamide
Figure imgf000072_0003
Following the method of Example 10, Procedure 1 , except that (a) the compound 3,10-dibromo-8,10-dichloro-6,1 1-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine is substituted for 3-bromo-8,10-dichloro- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine in Step A, and (b) methylamine is substituted for 3-aminomethylpyridine in Step C, the title compound is obtained. FABMS (MH+) = 528. FPT IC50 = 0.96 uM.
Example 51. 1-(3,10-Dibromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11-yl)-N-(3-pyridinylmethyl)-3- piperidinecarboxamide N1 -oxide (Isomer B)
Figure imgf000073_0001
Following the method of Example 10, Procedure 1 , except that (a) the compound 3,10-dibromo-8, 10-dichloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine is substituted for 3-bromo-8,10-dichloro- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine in Step A, and (b) 3-aminomethylpyridine-N-oxide is substituted for 3-aminomethylpyridine in Step C, the title compound is obtained. FABMS (MH+) = 619. FPT IC50 = 0.1 uM.
Example 52. 1-(3,10-Dibromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[2-(3-pyridinyl)ethyl]-3- piperidinecarboxamide
Figure imgf000073_0002
Following the method of example 10, procedure 1 , except that (a) the compound 3,10-dibromo-8,10-dichloro-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine is substituted for 3-bromo-8,10-dichloro- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine in Step A.and (b) 3- aminoethylpyridine is substituted for 3-aminomethylpyridine in Step C, the title compound is obtained. FABMS (MH+) = 617. FPT IC50 = 0.081 uM
Example 53. 1-(3,10-Dibromo-8-chloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[[1 -[(dimethylamino)acetyl]-4- piperidinyl]methyl]-3-piperidinecarboxamide
Figure imgf000074_0001
Following the method of Example 10, Procedure 1 , except that (a) the compound 3,10-dibromo-8,10-dichloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine is substituted for 3-bromo-8,10-dichloro- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine in Step A.and (b) dimethylaminoacetyl-4-piperidinylmethyl-3-amine is substituted for 3- aminomethylpyridine in Step C, the title compound is obtained. FABMS (MH+ ) = 694. FPT IC50 = 0.11 uM
Example 54. 1-(3,10-Dibromo-8-chloro-6,11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 -yl)-N-[3-(2-oxo-1 -pyrrolidinyl)propyl]-3- piperidinecarboxamide
Figure imgf000074_0002
Following the method of Example 10, Procedure 1 , except that (a) the compound 3,10-dibromo-8,10-dichloro-6,1 1-dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine is substituted for 3-bromo-8,10-dichloro- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine in Step A, and (b) 3-aminopropylpyrrolidinone amine is substituted for 3-aminomethylpyridine in Step C, the title compound is obtained. FABMS (MH+) = 637. FPT IC50 = 0.1 uM
PREPARATION OF STARTING MATERIALS
Starting materials useful in preparing the compounds of the present invention are exemplified by the following preparative examples, which should not be construed to limit the scope of the disclosure. The tricylic compounds (3.0) and substituted piperidinyl compounds (7.0) used as starting materials are known in the art and/or can be prepared using known methods, such as taught in U.S. Patents 5,089,496; 5,151 ,423; 4,454,143; 4,355,036; PCT /US94/11390 (WO95/10514); PCT/US94/11391 (WO 95/10515); PCT/US94/11392 (WO95/10516); Stanley R. Sandier and Wolf Karo, Organic Functional Group Preparations, 2nd Edition, Academic Press, Inc., San Diego, California, Vol. 1- 3, (1983); in J. March, Advanced Organic Chemistry, Reactions &
Mechanisms, and Structure, 3rd Edition, John Wiley & Sons, New York, 1346 pp. (1985); in G. R. Newkome (Ed.), Pyrdine and its Derivatives, John Wiley and Sons Inc., New York, N.Y., Vol. 1-5, (1984); A. J. Boulton and A. McKillop (Eds.), Comprehensive Heterocyclic Chemistry, Volume 2, Part 2A, Six Membered Rings With One Nitrogen Atom, Pergamon Press, Elmsford, New York, (1960-1985); and Chia-Lin J. Wang and Mark A. Wuonola, Recent Progress in the Synthesis and Reactions of Substituted Piperidines. A Review, Organic Preparations and Procedures International Vol 24, p. 585, (1992). The starting materials may also be prepared as taught in copending U.S. Application Serial No. 08/410,187 filed March 24, 1995, copending U.S.
Application Serial No. 08/577,951 filed December 22, 1995, and copending U.S. Application Serial No. 08/615,760 filed March 13, 1996; the disclosures being incorporated herein by reference. Alternative mechanistic pathways and analogous structures within the scope of the invention may be apparent to those skilled in the art.
For example, piperidinyl compounds of formula (7.0), wherein T = -CO- or -CR30R31- can be prepared by initially preparing a pyridine compound substituted with the requisite 2-, 3-, or 4 -(CH2)nCR30R31Z or -(CH2)nCOZ moiety, together with any optional -R5, -R6, -R7 and/or -R8 moieties, as described, in the references cited above. The 2-, 3- or 4-substituted pyridine compound can subsequently be reduced using conventional reduction procedures, such as catalytic hydrogenation, to give the desired piperidinyl compound (7.0). One skilled in the art will appreciate that in cases where -R5, -R6, -R7, -R8and/ or Z moieties also contain reducible groups, it may useful to utilize alternative methods.
The sulfonylpiperidinyl compounds of formula (7.0), wherein T= -SO2- can be prepared by reacting the appropriate 2-, 3-, or 4-hydroxy-N-blocked- piperidine with a suitable chlorinating agent such as thionyl chloride to obtain the 2-, 3-, or 4-chloro-N-blocked piperidine, using N-blocking groups such as benzyloxycarbonyl or tert-butoxycar bonyl. The 2-,3-, or 4-chloro-N-blocked piperidine can then be reacted with sodium bisulfite to obtain the corresponding 2-, 3-, or 4-sulfonic acid N-blocked piperidine sodium salt. This salt is then reacted with an appropriate chlorinating agent such as phosphorus pentachloride or phosphorus oxychloride to obtain the corresponding 2-, 3- or 4-sulfonylchloride-N-blocked piperidine. This sulfonyl chloride is then reacted with the corresponding agent containing the desired Z group (i.e. amines, alkylating agents and the like) to obtain the desired sulfonylpiperidine (7.0).
The sulfoxylpiperidine wherein T= -SO- (with the proviso that Z is not -NR40R42) can be prepared by reacting the appropriate 2-, 3-, or 4-hydroxy-N- blocked-piperidine with a suitable chlorinating agent such as thionyl chloride to obtain the 2-, 3-, or 4-chloro-N-blocked piperidine, using N-blocking groups such as benzyloxycarbonyl or tert-butoxycar bonyl. The 2-, 3-, or 4-chloro-N- blocked piperidine can then reacted with the corresponding substituted sulfide (i.e. arylsulfide, alkylsulfides and the like) to obtain the appropriate 2-, 3-, or 4- sulfide-N-blockedpiperidine. This compound can then be reacted with an oxidizing agent such as meta-chloroperbenzoic acid to obtain the desired sulfoxylpiperidine (7.0).
PREPARATIVE EXAMPLE 1. 4-Piperidinyl-N-(4-pyridinvncarboxamide
Figure imgf000076_0001
Step A:
1 -N-(tert -Butoxycarbonyl-4-piperidine carboxylic acid or 1-N-(fe/ -butoxycarbonyl)isonipecotic acid
Figure imgf000077_0001
Isonipecotic acid (5g; 1 equivalent) is dissolved in water (50 ml) and a solution of di-tert -butyldicarbonate (8.62g; 1.02 equivalents) in THF (70 ml) is added with stirring. The mixture is stirred at 80°C for 2 h and then evaporated to dryness. The residue is partitioned between dichloromethane and brine and the dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (30 X 5cm) using 15% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (4.3109g; 49% yield), CIMS: m/z 230 (MH+)- Step B: 1-N-(tert -Butoxycarbonyl)-4-piperidinyl-N-(4-pyridinyl)carboxamide
Figure imgf000077_0002
1-N-(terf -Butoxycarbonyl)-4-piperidinecarboxylic acid (1.218; 1 equivalent) (prepared as described in Step A above), DEC (1.0184g; 1 equivalent), HOBT (0.7179g; 1 equivalent) and N-methylmorpholine (0.5841ml; 1 equivalent) are dissolved in anhydrous DMF (30 ml) and the mixture is stirred under argon at 25°C for 19 h. The solution is evaporated to dryness. The residue is taken up in dichloromethane and washed with water. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60 X 2.5 cm) using 5% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.8142g; 50% yield), CIMS: m/z 306 (MH+).
Step C: 4-Piperidinyl-N-(4-pyridinyl)carboxamide
Figure imgf000077_0003
1-N-(terf -Butoxycarbonyl)-4-piperidinyl-N-(4-pyridyl)carboxamide (1g; 1 equivalent) is dissolved in 10% (v/v) concentrated sulfuric acid in dioxane (24.36ml) and the mixture is stirred at 25°C for 0.5 h. The mixture is poured into water (150 ml) and neutralized with Amberlite IRA401S(OH") ion exchange resin (300ml). The resin is eluted with water (1500 ml) and the eluant is evaporated to give the title compound (0.4258g; 63% yield), CIMS: m/z 206 (MH+).
PREPARATIVE EXAMPLE 2
1-[3-Bromo-8-chloro-6,11-dihydr o-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11- yl]-4-piperidinecarboxylate
Figure imgf000078_0001
Procedure 1 , Step A:
Ethyl 1-[3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11 -yl]-4-piperidinecarboxylate
Figure imgf000078_0002
3-Bromo-8,11 -dichloro-6, 11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine (1g; 1 equivalent) and ethyl isonipecotate (2.3735ml) (5 equivalents) are dissolved in dry THF (20ml) and the mixture was stirred at 25°C under argon for 19h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.0N sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (30X5cm) using 0.75% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (1.5134g; 100% yield), CIMS: m/z 463.15 (MH+). Step B:
1 -[3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11 ' yl]-4-piperidinecarboxylate
Figure imgf000079_0001
Ethyl 1 -[3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta [1 ,2-b]pyridin -11-yl]-4-piperidinecarboxylate (0.250g; 1 equivalent) (prepared as described in Step A above), is dissolved in ethanol (3ml) and dichloromethane (3ml) and 1.0M lithium hydroxide in water (1.3044ml; 2.42 equivalents) is added The mixture is stirred at 50°C for 5h. 1.0N Hydrochloric acid (1.5169ml ) (2.81 equivalents) is added and the solution is evaporated to dryness after stirring for 5 min. to give the title compound which is used without further purification.
Procedure 2:
1 -[3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridin-11-
YL]-4-piperidinecarboxylate
Figure imgf000079_0002
3-Bromo-8, 11 -Dichloro-6, 11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b] pyridine (prepared as described in Preparative Example 40, Step B in IN0291K) (0.5g; 1 equivalent), isonipecotic acid (0.3978g; 2 equivalents) and 4-N- methylmor pholine (0.847ml; 5 equivalents) are dissolved in anhydrous DMF (9.6ml) and the mixture is heated at 80°C for 16.5h. The solution is evaporated to dryness and the product is chromatographed on a silica gel column (60X2.5cm) using 10% ethyl acetate in hexane, followed by 1% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.2426g; 36% yield), CIMS: m.z 435.1 (MH+).
PREPARATIVE EXAMPLE 3
4-(Aminomethyl)-1 -N-(fe/t -butoxycarbonyl)piper idine
Figure imgf000080_0001
Ref.: J. D. Prugh, L. A. Birchenough and M. S. Egbertson, Synthetic Communications, 22(16), 2357-2360 (1992).
Step A: 4-(Benzylidineaminomethyl)piperidine
Figure imgf000080_0002
4-Aminomethylpiperidine (11.4g) (1 equivalent) is dissolved in anhydrous toluene (125ml) and benzaldehyde (10.6g) (1 equivalent) is added. The mixture is heated at 120°C under reflux for 4h, using a Dean-Stark trap to remove water. The crude solution of the title compound is used directly in Step B below.
Step B:
1 -N-(tert -Butoxycarbonyl)-4-(benzylidineaminomethyl)piperidine
Figure imgf000080_0003
4-(Benzylideneaminomethyl)piperidine in toluene (From Step A above) is treated with di-te/ -butyldicarbonate (24g) (1.1 equivalents) in portions over 0.5h. The mixture is stirred at 25°C for 69h. The solution is evaporated to dryness to give the title compound which is used directly in Step C below.
Step C: 4-(Aminomethyl)-1-N-(ter_ -butoxycarbonyl)piperidine
Figure imgf000081_0001
1 -N-(te/ϊ -Butoxycarbonyl)-4-(benzylideneaminomethyl)piperidine (prepared as described in Step B above) is dissolved in 1.ON aqueous potassium hydrogen sulfate (220ml) and the mixture is stirred at 25°C for 4h. The solution is extracted with ether (3X200ml) and the ether is discarded. The aqueous layer is adjusted to pH 12.5 using 50% aqueous sodium hydroxide and the solution is then saturated with solid sodium chloride and extracted with dichloromethane. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60 X 5cm) using 1% increasing to 7% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (9.82g; 46% yield), an oil, CIMS: m/z 215 (MH+).
PREPARATIVE EXAMPLE 4 1-N-Benzyl-4-(aminomethyl)piperidine
Figure imgf000081_0002
Step A: 1-N-Benzyl-4-piperidinecarboxamide
Figure imgf000081_0003
4-Piperidinecarboxamide (5g; 1 equivalent) and triethylamine (16.3ml) (3 equivalents) are dissolved in anhydrous dichloromethane (30ml) and anhydrous DMF (80ml). A solution of benzyl bromide (4.55ml) (0.98 equivalents) in anhydrous dichloromethane (10ml) is added dropwise over 10 min and the mixture is stirred at 25°C for 22h. The mixture is filtered and the filtrate is evaporated to dryness. The product is chromatographed on a silica gel column (60X5cm) using dichloromethane (1 litre) and then 5% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (6.15g; 72% yield), CIMS: m/z 219.05 (MH+).
Step B: 1 -N-Benzyl-4-(aminomethyl)piperidine
Figure imgf000082_0001
1-N-Benzyl-4-piperidinecarboxamide (1g; 1 equivalent) (prepared as described in Step A above) is dissolved in anhydrous THF (25ml). Lithium aluminum hydride (0.2173g) (1.25 equivalents) in anhydrous THF (5.726ml) is added dropwise over 0.5h and the mixture is heated under reflux under nitrogen for 20h. The mixture is cooled and diluted with dichloromethane (750ml) and washed with 1.0N sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 2% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.5237g; 56% yield), FABMS: m/z 205.4 (MH+).
PREPARATIVE EXAMPLE 5 Step A: 4-(N-Benzyloxycarbonylaminomethyl)piperidine
Figure imgf000082_0002
4- Aminomethylpiperidine (1g; 1 equivalent) and DMAP (0.054g; 0.05 equivalents) are dissolved in anhydrous dichloromethane (40 ml). N-
Benzyloxycarbonylimidazole (1.7709g; 1 equivalent) [prepared as described in: S. K. Sharma, M. J. Miller and S. M. Payne, J. Med. Chem., 32, 357-367 (1989)] is added and the mixture is stirred at 25°C for 23 h. The solution is diluted with dichloromethane and washed with 1.0N sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 3% increasing to 7% (10% concentrated ammonium hydroxide in methano!)-dichloromethane as the eluant to give the title compound (1.0719g; 49% yield ), FABMS: m/z 249.3 (MH+).
Step B: 1 -N-(Benzyloxycarbonyl)-4-[N-(terf -butoxycarbonyl)aminomethyl]piperidine
Figure imgf000083_0001
4-(N-Benzyloxycarbonylaminomethyl)piperidine (0.6814g; 1 equivalent) (prepared as described in Step A above) is dissolved in anhydrous toluene (5 ml) and di-tert -butyldicarbonate (0.599g; 1 equivalent) in anhydrous toluene (5 ml) is added dropwise. The mixture is stirred at 0°C for 2h and at 25°C for 20 h. The solution is evaporated to dryness and the residue is taken up in dichloromethane and washed with 1.0N sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (60X2.5cm) using 0.5% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.9314g; 97% yield), FABMS: m/z 349.3 (MH+).
Step C: 4-[(tert -Butoxycarbonylamino)methyI]piperidine
Figure imgf000083_0002
1-N-(Benzyloxycarbonyl)-4-[(terf -butoxycarbonylamino)methyl]-piperidine (0.4g) (1 equivalent) (prepared as described in Step B above) is dissolved in methanol (16ml) and 5% Pd-C (0.0638g) is added. The mixture is hydrogenated at 30 psi at 25°C for 17h. The catalyst is removed by filtration through Celite which is washed with methanol. The combined filtrates are evaporated to dryness. The residue is taken up in dichloromethane and washed with 1.ON sodium hydroxide. The dichloromethane layer is dried over magnesium sulfate, filtered and evaporated to dryness. The product is chromatographed on a silica gel column (45X2.5cm) using 2% increasing to 7% (10% concentrated ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.2001g; 81% yield), FABMS: m/z 215.4 (MH+).
PREPARATIVE EXAMPLE 6 Step A
Figure imgf000084_0001
Combine 40.0 g (0.124 mole) of the starting ketone and 200 mL of H2SO4 and cool to 0°C. Slowly add 13.78 g (0.136 mole) of KNO3 over a period of 1.5 hrs., then warm to room temperature and stir overnight. Work up the reaction using substantially the same procedure as described for Preparative Example 4, Step A. Chromatograph (silica gel, 20%, 30%, 40%, 50% EtOAc/hexane, then 100% EtOAc) to give 28 g of the 9-nitro product, along with a smaller quantity of the 7-nitro product and 19 g of a mixture of the 7-nitro and 9-nitro compounds.
Step B
Figure imgf000084_0002
React 28 g (76.2 mmol) of the 9-nitro product of Step A, 400 mL of 85% EtOH/water, 3.8 g (34.3 mmol) of CaCl2 and 38.28 g (0.685 mole) of Fe using substantially the same procedure as described for Preparative Example 4, Step C, to give 24 g of the product Step C
Figure imgf000085_0001
Combine 13 g (38.5 mmol) of the product of Step B, 140 mL of HOAc and slowly add a solution of 2.95 mL (57.8 mmol) of Br2 in 10 mL of HOAc over a period of 20 min. Stir the reaction mixture at room temperature, then concentrate in vacuo to a residue. Add CH2CI2 and water, then adjust to pH 8-9 with 50% NaOH (aqueous). Wash the organic phase with water, then brine and dry over Na2S04. Concentrate in vacuo to give 11.3 g of the product.
Step D
Figure imgf000085_0002
Cool 100 mL of concentrated HCI (aqueous) to 0°C, then add 5.61 g (81.4 mmol) of NaNθ2 and stir for 10 min. Slowly add (in portions) 11.3 g (27.1 mmol) of the product of Step C and stir the mixture at 0°-3°C for 2.25 hrs. Slowly add (dropwise) 180 mL of 50% H3PO2 (aqueous) and allow the mixture to stand at 0°C overnight. Slowly add (dropwise) 150 mL of 50% NaOH over 30 min., to adjust to pH = 9, then extract with CH2CI2. Wash the extract with water, then brine and dry over Na2S04. Concentrate in vacuo to a residue and chromatograph (silica gel, 2% EtOAc/ CH2CI2) to give 8.6 g of the product. Step E
Figure imgf000085_0003
Combine 8.6 g (21.4 mmol) of the product of Step D and 300 mL of MeOH and cool to 0°-2°C. Add 1.21 g (32.1 mmol) of NaBH4 and stir the mixture at ~0°C for 1 hr. Add another 0.121 g (3.21 mmol) of NaBH4, stir for 2 hr. at 0°C, then let stand overnight at 0°C. Concentrate in vacuo to a residue then partition the residue between CH2CI2 and water. Separate the organic phase and concentrate in vacuo (50°C) to give 8.2 g of the product. Step F. 3, 10-dibromo-8, 11 -dichloro-6, 11 -dihydro-5H- benzo[5,6]cyclohepta[1 ,2-b]pyridine
Figure imgf000086_0001
Combine 8.2 g (20.3 mmol) of the product of Step E and 160 mL of CH2CI2, cool to 0°C, then slowly add (dropwise) 14.8 mL (203 mmol) of SOCI2 over a 30 min. period. Warm the mixture to room temperature and stir for 4.5 hrs., then concentrate in vacuo to to give the title compound.
PREPARATIVE EXAMPLE 7. N-(3-Pyridylmethyl)-4-piperidineacetamide
Figure imgf000086_0002
Step A. -tert -butoxycarbonyl-N-(3-pyridylmethyl)-4-piperidineacetamide
Figure imgf000086_0003
1-te/t -Butoxycarbonyl-4-piperidineacetic acid (5g, 20.55mmoles) (prepared as described in Preparative Example 17, Step A in IN0291 K), 3- aminomethylpyridine (2.72g, 26.7mmoles), DEC.HCI (5.12g, 26.7mmoles), HOBT (3.61 g, 26.7mmoles) and NMM (2.94ml, 26.7mmoles) are dissolved in anhydrous DMF (100ml) and the mixture is stirred under argon at 25°C for 22h. The solution is evaporated to dryness and the residue is dissolved in dichloromethane, washed with 1 N NaOH, dried over magnesium sulfate, filtered and evaporated to dryness. The residue is chromatographed on silica gel using 2% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (6.05g, 77%), ESIMS: m/z 334.1 (MH+).
Step B.
N-(3-Pyridylmethyl)-4-piperidineacetamide
Figure imgf000087_0001
1 -tert -Butoxycarbonyl-N-(3-pyridylmethyl)-4-piperidineacetamide (5.59g, 16.76mmoles) is dissolved in methanol (100ml) and 10% cone, sulfuric acid in dioxane (v/v) (250ml) is added. The mixture is stirred at 25°C for 2h and the neutralized with Bio Rad AG-1X8 (OH") resin. The resin is washed with methanol and the eluate is evaporated to dryness. The residue is chromatographed on silica gel using 5%-20%-30% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give 3.64 g (93% yield) of the title compound: ESIMS: m/z 234.1 (MH+).
PREPARATIVE EXAMPLE
Figure imgf000087_0002
Step A.
4-Piperidinepropionic acid
Figure imgf000087_0003
3-(4-Pyridyl)acrylic acid (2g, 13.4mmoles) is dissolved in water (70ml) and concentrated hydrochloric acid (1 ml). 10% Pd-C (1.5 spatulas) is added and the mixture is hydrogenated at 25°C at 55psi for 72h. The mixture is filtered through Celite® and then passed over a bed of Bio Rad AG 1 -X8 (OH") resin. The resin is washed with water and the combined eluates are evaporated to dryness to give the title compound that is used in Step B without further purification.
Step B. x -tert -Butoxycarbonyl-4-piperidinepropionic acid
Figure imgf000088_0001
4-Piperidinepropionic acid (13.4mmoles) (prepared as described in Step A above), di-te/t -butyldicarbonate (3.22g, 14.75mmoles) and sodium hydroxide (0.5364g, 13.4mmoles) are dissolved in THF-water (1 :1) (40ml) and the mixture is stirred at 25°C for 18h. The mixture is passed over Bio Rad 50WX4 (H+) resin (15ml bed) and the resin is washed with THF-water. The combined eluates are evaporated to dryness and then azeotroped with THF to give the title compound (2.72g, 79%), FABMS: m/z 258.1 (MH+).
Step C.
N-(3-P amide
Figure imgf000088_0002
1-fert -Butoxycarbonyl-4-piperidinepropionic acid (2g, 7.77mmoles), 3- (aminomethyl)pyridine (1.029ml, 10.1mmoles), DEC.HCI (1.937g,
10.1 mmoles), HOBT (1.365g, 10.1 mmoles) and NMM (1.111ml, 10.1 mmoles) are dissolved in anhydrous DMF (25ml) and the mixture is stirred under argon at 25°C for 20h. The solution is evaporated to dryness and the residue is taken up in dichloromethane, washed with 0.3N NaOH, dried over magnesium sulfate, filtered and evaporated to dryness. The residue is chromatographed on silica gel using 1.5%-2.5% (10% cone, ammonium hydroxide in methanol)- dichloromethane as the eluant to give the title compound (2.555g, 95%), ESIMS: m/z 348.1 (MH+).
Step D. N-(3-Pyridylmethyl)-4-piperidinepropanamide
Figure imgf000089_0001
N-(3-Pyridylmethyl)-1 -tert -butoxycarbonyl-4-piperidinepropanamide (2.222g, 6.4mmoles) is dissolved in methanol (38.15ml) and 10% cone. H2SO4 in dioxane (v/v) (95.38ml) is added and the mixture is stirred under argon at 25°C for 1.5h. The volume is reduced to half and the mixture is basified to pH 12 with 50% NaOH aq and extracted with dichloromethane. The latter is dried over magnesium sulfate, filtered and evaporated to dryness. The residue is chromatographed on silica gel using 10% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.9586g, 61 %), CIMS: m/z 248.25 (MH+).
PREPARATIVE EXAMPLE 9. Ethyl 4-piperidineacetate
Figure imgf000089_0002
Ethyl -tert -butoxycarbonyl-4-piperidineacetate
Figure imgf000089_0003
1-tert -Butoxycarbonyl-4-piperidineacetic acid (1g, 4.1mmoles) (prepared as described in Preparative Example 17, Step C in IN0291K), ethanol (200 proof) (0.284g, 0.362ml, 6.2mmoles), DEC.HCI (1.18g, 6.2mmoles), HOBT (0.8331 g, 6.2mmoles) and NMM (0.624g, 0.678ml, 6.2mmoles) are dissolved in anhydrous DMF (30ml) and the mixture is stirred at 25°C under argon for 24h. The solution is evaporated to dryness and the residue is dissolved in dichloromethane, washed with satd, NaHCθ3 aq, water, dried over magnesium sulfate, filtered and evaporated to dryness. The residue is chromatographed on silica gel using 0.5% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (0.682g, 61%), ESIMS: m/z 272.0 (MH+).
Step B. Ethyl 4-piperidineacetate
Figure imgf000090_0001
Ethyl 1-fert -butoxycarbonyl-4-piperidineacetate (0.6g, 2.2mmoles) is dissolved in ethanol (30ml) and 10% cone. H2SO4 in dioxane (v/v) (30ml) is added and the mixture is stirred at 25°C for 2h. The mixture is passed over a bed of Bio Rad AG1-X8 (OH') resin and the resin is then eluted with ethanol. The combined eluates are evaporated to dryness and the residue is chromatographed on silica gel using 1% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound.
PREPARATIVE EXAMPLE 10 1 -(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyr idin-11-yl)-4-piperidineacetic acid
Figure imgf000090_0002
Step A.
Ethyl 1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyr idin-11 -yl)-4-piperidineacetate
Figure imgf000090_0003
3,10-Dibromo-8,11-dichloro-6,11-dihydro-5H-benzo[5,6] cyclohepta[1 ,2- b]pyridine (prepared as described in Preparative Example 6, Step F) (0.486g, 1.15mmoles) is dissolved in anhydrous THF (5ml). Ethyl 4-piperidineacetate (prepared as described in Preprative Example 9, Step B) (0.6241 g, 2.3mmoles) and triethylamine (0.321 ml, 2.3mmoles) in anhydrous THF (5ml) are added and the mixture is stirred at 25°C for 24h. The solution is evaporated to dryness and the residue is dissolved in dichloromethane and washed with 1 N NaOH , dried (MgS04), filtered and evaporated to dryness. The product is chromatographed on silica gel using 5% (10% cone, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound.
Step B.
1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11-yl)-4-piperidineacetic acid
Figure imgf000091_0001
Ethyl 1-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1 ,2- b]pyridin-11-yl)-4-piperidineacetate (0.3g, 0.5mmoles) (prepared as described in Step A above) is dissolved in ethanol (4ml) and dichloromethane (4ml) and 1 M lithium hydroxide in water (1.21mmoles) is added. The mixture is stirred at 50°C for 5h. 1N Hydrochloric acid (1.21mmoles) is added and the solution is evaporated to dryness to give the title compound which is used without further purification.
ASSAYS
1. In vitro enzyme assays: FPT IC50 (inhibition of farnesyl protein transferase, in vitro enzyme assay) are determined by the methods disclosed in WO/10515 or WO 95/10516. The data demonstrate that the compounds of the invention are inhibitors of Ras-CVLS farnesylation by partially purified rat brain farnesyl protein transferase (FPT). The data also show that there are compounds of the invention which can be considered as potent (IC50 <10 μM) inhibitors of Ras-CVLS farnesylation by partially purified rat brain FPT. Under the test protocols employed, there were certain compounds within the scope of the present invention which did not exhibit activity. It is believed that such compounds would exhibit activity under a different test protocol.
2. Cell-based assay. COS IC50 values refer to the COS cells activity inhibition of Ras processing, are determined by the methods disclosed in WO/10515 or WO 95/10516.
For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transder mally. The transdermal compositions can take the form of creams, lotions, aerosols and or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. Preferably the compound is administered orally. Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose. The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 300 mg, according to the particular application.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
The amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended dosage regimen is oral administration of from 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to block tumor growth. The compounds are non-toxic when administered within this dosage range.
The following are examples of pharmaceutical dosage forms which contain a compound of the invention. The scope of the invention in its pharmaceutical composition aspect is not to be limited by the examples provided.
Pharmaceutical Dosage Form Examples EXAMPLE A-Tablets
No. Ingredients mg/tablet mg/tablet
1. Active compound 100 500
2. Lactose USP 122 113
3. Corn Starch, Food Grade, 30 40 as a 10% paste in Purified Water
4. Corn Starch, Food Grade 45 40
5. Magnesium Stearate 3 7
Total 300 700
Method of Manufacture Mix Item Nos. 1 and 2 in a suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weigh on a suitable tablet machine.
EXAMPLE B-Capsules
No. Ingredient mg/capsule mg/capsule
1. Active compound 100 500
2. Lactose USP 106 123
3. Corn Starch, Food Grade 40 70
4. Magnesium Stearate NF 7 7
Total 253 700 Method of Manufacture
Mix Item Nos. 1 , 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.
While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula:
Figure imgf000095_0001
or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c and d represents N or NR9 wherein R9 is O", -CH3 or
-(CH2)nC02H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR1 or CR2; or each of a, b, c, and d are independently selected from CR1 or CR2; each R1 and each R2 is independently selected from H, halo, -CF3, -OR10, -COR10, -SR10, -S(O)tR11 (wherein t is 0, 1 or 2), -SCN, -N(R1 )2l -NR10R11 , -NO2, -OC(0)R °, -C02R1°, -OC02R1 1, -CN, -NHC(0)R10, -NHS02R1°, -CONHR10, -CONHCH2CH2OH, -NR10COOR1 1 , -SR1 1C(0)OR11 , -SR11N(R75)2 wherein each R75 is independently selected from H and -C(0)OR11 , benzotriazol-1-yloxy, tetrazol-5-ylthio, or substituted tetrazol-5- ylthio, alkynyl, alkenyl or alkyl, said alkyl or alkenyl group optionally being substituted with halo, -OR10 or -C02R10;
R3 and R4 are the same or different and each independently represents H, any of the substituents of R1 and R2, or R3 and R4 taken together represent a saturated or unsaturated C5-C7 fused ring to the benzene ring (Ring III);
R5, R6, R7 and R8 each independently represents H, -CF3, -COR10, alkyl or aryl, said alkyl or aryl optionally being substituted with -OR10, -SR10, -S(0)tR11 , -NR1°COOR11, -N(R10)2, -N02, -COR10, -OCOR10, -OC02R11 , -C02R10, OPO3R10, or R5 is combined with R6 to represent =0 or =S and/or R7 is combined with R8 to represent =0 or =S;
R10 represents H, alkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, aryl, aralkyl or -NR 0R42 wherein R40 and R42 independently represent H, aryl, alkyl, aralkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; R1 1 represents alkyl or aryl; the dotted line between carbon atoms 5 and 6 represents an optional double bond, such that when a double bond is present, A and B independently represent -N02, -R10, halo, -OR11, -OC02R11 or -OC(0)R1°, and when no double bond is present between carbon atoms 5 and 6, A and B each independently represent H2) -(OR11)2, H and halo, dihalo, alkyl and H, (al yl)2, -H and -OC(0)R1°, H and -OR10, oxy, aryl and H, =NOR10 or -O- (CH2)p-0- wherein p is 2, 3 or 4; n is 0 (zero), 1 , 2, 3, 4, 5 or 6;
T is -CO-; -SO-; -S0 -; or -CR30R31- wherein R30 and R31 independently represent H, alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; and Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR40, -SR40, -CR 0R42, -NR40R42,
Figure imgf000096_0001
wherein n, R40 and R42 are defined hereinbefore, m is 2, 34, 5, 6, 7 or 8; q is 0 (zero), 1 or 2; and R14 represents H, C1-6 alkyl, aralkyl, heteroaryl, acyl, carboxamido, carboxamidoalkyl, cyano, alkoxycarbonyl, aralkyloxycarbonyl, D- and L-amino acids covalently bonded through the carboxyl group, imido, imidamido, sulfamoyl, sulfonyl, dialkylphosphinyl, N-glycosyl,
Figure imgf000096_0002
CR 6Hn5
Figure imgf000096_0003
-C(NHCH3)=CHN02l with the proviso that when T is -SO-, Z is not -NR40R42.
2. The compound of claim 1 wherein a is N; b, c and d are carbon; A and B each represent H2 and the optional double bond is absent.
3. The compound of claim 2 wherein R1 and R4 are H and R2 and R3 are halo selected from chloro and bromo; or R1 is H and R2, R3 and R4 are halo selected from chloro and bromo.
4. The compound of claim 3 wherein R2 and R3 are halo in the 3- and the 8-position on the ring structure; or R2, R3 and R4 are in the 3-, 8- and 10- position on the ring structure.
5. The compound of claim 4 wherein R2 is Br and R3 is Cl in the 3- and the 8-position on the ring structure; or R2 is Br, R3 is Cl and R4 is Br in the 3-, 8- and 10- position on the ring structure.
6. The compound of claim 5 wherein each of R5, R6, R7 and R8 is H.
7. The compound of claim 6 wherein the moiety -(CH2)n-T-Z is bonded at the 2-, 3- or 4-position on the piperdinyl ring.
8. The compound of claim 7 wherein the moiety -(CH2)n-T-Z is bonded at the 2- or 3- position on the piperdinyl ring.
9. The compound of claim 8 wherein n is zero, 1 or 2; T is -CO- and Z is -NR40R42 wherein R40 and R42 independently represent H, aryl, alkyl, aralkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroalkyl, cycloalkyl or cycloalkylalkyl; or Z is
Figure imgf000098_0001
wherein R40 is defined hereinbefore, m is 2, 3 or 4; q is O (zero), 1 or 2; and R14 represents H, C1-6 alkyl, aralkyl, heteroaryl, acyl, carboxamido, carboxamidoalkyl, cyano, alkoxycarbonyl, aralkyloxycarbonyl imido, imidamido, sulfamoyl, sulfonyl, dialkylphosphinyl, N-glycosyl or-C(NHCH3)=CHN02.
10. The compound of claim 9 wherein n is zero; Z is -NR40R42 wherein
R40 represents H and R42 represents heteroarylalkyl.
11. The compound of claim 10 wherein R40 is H and R42 is 3-pyridylmethyl.
12. The compound of claim 9 selected from any of the title compounds of Examples 1 -54.
13. The compound of claim 12 which is selected from
Figure imgf000099_0001
and Isomer D3 amide or a pharmaceutically acceptable salt thereof.
14. The compound of claim 13 which is
Figure imgf000100_0001
15. A pharmaceutical composition for inhibiting the abnormal growth of cells comprising an effective amount of compound of Claim 1 in combination with a pharmaceutically acceptable carrier.
16. A method for inhibiting the abnormal growth of cells comprising administering an effective amount of a compound of claim 1.
17. The method of claim 16 wherein the the cells inhibited are tumor cells expressing an activated ras oncogene.
18. The method of claim 16 wherein the cells inhibited are pancreatic tumor cells, lung cancer cells, myeloid leukemia tumor cells, thyroid follicular tumor cells, myelodysplastic tumor cells, epidermal carcinoma tumor cells, bladder carcinoma tumor cells or colon tumors cells.
19. The method of claim 16 wherein the inhibition of the abnormal growth of cells occurs by the inhibition of ras farnesyl protein transferase.
20. The method of claim 16 wherein the inhibition is of tumor cells wherein the Ras protein is activated as a result of oncogenic mutation in genes other than the Ras gene.
PCT/US1997/015903 1996-09-13 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase WO1998011098A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP97941477A EP0931078B1 (en) 1996-09-13 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
JP10513762A JP2001500507A (en) 1996-09-13 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl protein transferase
IL12890797A IL128907A0 (en) 1997-09-11 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
HU0000191A HUP0000191A2 (en) 1996-09-13 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
AU43376/97A AU4337697A (en) 1996-09-13 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
NZ334452A NZ334452A (en) 1996-09-13 1997-09-11 Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase (FTase)
BR9712826-0A BR9712826A (en) 1996-09-13 1997-09-11 New tricyclic piperidinyl compounds useful as farnesyl protein transferase inhibitors
CA002265763A CA2265763A1 (en) 1996-09-13 1997-09-11 Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
SK330-99A SK33099A3 (en) 1996-09-13 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
DE69736950T DE69736950T2 (en) 1996-09-13 1997-09-11 TRICYCLIC PIPERDINYL DERIVATIVES USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
NO991233A NO991233L (en) 1996-09-13 1999-03-12 New tricyclic piperidinyl compounds useful as inhibitors of farnesyl protein transferase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71370396A 1996-09-13 1996-09-13
US08/713,703 1996-09-13

Publications (1)

Publication Number Publication Date
WO1998011098A1 true WO1998011098A1 (en) 1998-03-19

Family

ID=24867181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015903 WO1998011098A1 (en) 1996-09-13 1997-09-11 Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase

Country Status (19)

Country Link
EP (1) EP0931078B1 (en)
JP (1) JP2001500507A (en)
KR (1) KR20000036104A (en)
CN (1) CN1237170A (en)
AT (1) ATE345338T1 (en)
AU (1) AU4337697A (en)
BR (1) BR9712826A (en)
CA (1) CA2265763A1 (en)
CZ (1) CZ84199A3 (en)
DE (1) DE69736950T2 (en)
ES (1) ES2276435T3 (en)
HU (1) HUP0000191A2 (en)
ID (1) ID21218A (en)
NO (1) NO991233L (en)
NZ (1) NZ334452A (en)
PL (1) PL332241A1 (en)
SK (1) SK33099A3 (en)
TR (1) TR199901274T2 (en)
WO (1) WO1998011098A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6329385B1 (en) 1998-01-21 2001-12-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2002056884A2 (en) * 2001-01-22 2002-07-25 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2010011653A1 (en) * 2008-07-23 2010-01-28 Schering Corporation Tricyclic heterocycle derivatives as histamine h3 antagonists
US7732459B2 (en) 2002-11-13 2010-06-08 Millennium Pharmaceuticals, Inc. CCR1 antagonists and methods of use therefor
US8071624B2 (en) * 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522662A (en) * 2006-10-06 2009-09-02 博士伦公司 Quinolone carboxylic acids, derivatives thereof, and methods of making and using same
US7632944B2 (en) * 2007-01-24 2009-12-15 Bausch & Lomb Incorporated Quinolone carboxylic acids, derivatives thereof, and methods of making and using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593417A (en) * 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
EP0396083A1 (en) * 1989-05-01 1990-11-07 Schering Corporation Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use
WO1992000293A1 (en) * 1990-06-22 1992-01-09 Schering Corporation Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylidene and piperazine compounds and compositions
WO1995010515A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1995010516A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593417A (en) * 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
EP0396083A1 (en) * 1989-05-01 1990-11-07 Schering Corporation Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use
WO1992000293A1 (en) * 1990-06-22 1992-01-09 Schering Corporation Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylidene and piperazine compounds and compositions
WO1995010515A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1995010516A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329385B1 (en) 1998-01-21 2001-12-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6288084B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002056884A2 (en) * 2001-01-22 2002-07-25 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002056884A3 (en) * 2001-01-22 2003-09-12 Schering Corp Treatment of malaria with farnesyl protein transferase inhibitors
WO2002080895A3 (en) * 2001-04-06 2003-11-06 Schering Corp Treatment of malaria with farsenyl protein transferase inhibitors
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US9663537B2 (en) 2001-11-21 2017-05-30 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use
US7732459B2 (en) 2002-11-13 2010-06-08 Millennium Pharmaceuticals, Inc. CCR1 antagonists and methods of use therefor
US7977350B2 (en) 2002-11-13 2011-07-12 Millennium Pharmaceuticals, Inc. CCR1 antagonists and methods of use therefor
US9334283B2 (en) 2002-11-13 2016-05-10 Millennium Pharmaceuticals, Inc. CCR1 antagonists and methods of use thereof
US8071624B2 (en) * 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2010011653A1 (en) * 2008-07-23 2010-01-28 Schering Corporation Tricyclic heterocycle derivatives as histamine h3 antagonists

Also Published As

Publication number Publication date
ES2276435T3 (en) 2007-06-16
HUP0000191A2 (en) 2001-04-28
EP0931078B1 (en) 2006-11-15
SK33099A3 (en) 2000-05-16
CZ84199A3 (en) 1999-11-17
ID21218A (en) 1999-05-06
JP2001500507A (en) 2001-01-16
PL332241A1 (en) 1999-08-30
AU4337697A (en) 1998-04-02
CA2265763A1 (en) 1998-03-19
EP0931078A1 (en) 1999-07-28
NZ334452A (en) 2000-09-29
TR199901274T2 (en) 1999-10-21
ATE345338T1 (en) 2006-12-15
DE69736950D1 (en) 2006-12-28
KR20000036104A (en) 2000-06-26
NO991233D0 (en) 1999-03-12
NO991233L (en) 1999-05-12
CN1237170A (en) 1999-12-01
DE69736950T2 (en) 2007-09-20
BR9712826A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
US6239140B1 (en) Compounds useful for inhibition of farnesyl protein transferase
EP0931078B1 (en) Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
EP0989979A1 (en) Novel n-substituted urea inhibitors of farnesyl-protein transferase
EP0931077A1 (en) Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase
EP0927178B1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1998057960A1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
EP0927181A1 (en) Tricyclic compounds useful as fpt inhibitors
US5965570A (en) Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
WO1998011091A2 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
US6689789B2 (en) Compounds useful for inhibition of farnesyl protein transferase
MXPA99002426A (en) Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
EP0991637A1 (en) Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
CA2293373C (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
NZ501615A (en) Benzo[5,6]cyclohepta[1,2-b] pyridine derivatives useful for inhibition of farnesyl protein transferase
EP0927179B1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
EP0942906B1 (en) Compounds useful for inhibition of farnesyl protein transferase
MXPA99012061A (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199599.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 334452

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2265763

Country of ref document: CA

Ref document number: 2265763

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-841

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1997941477

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 33099

Country of ref document: SK

Ref document number: PA/a/1999/002426

Country of ref document: MX

Ref document number: 1019997002127

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 513762

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999/01274

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1997941477

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-841

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997002127

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019997002127

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-841

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1997941477

Country of ref document: EP